WO2007110215A1 - Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase - Google Patents

Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase Download PDF

Info

Publication number
WO2007110215A1
WO2007110215A1 PCT/EP2007/002637 EP2007002637W WO2007110215A1 WO 2007110215 A1 WO2007110215 A1 WO 2007110215A1 EP 2007002637 W EP2007002637 W EP 2007002637W WO 2007110215 A1 WO2007110215 A1 WO 2007110215A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
crc
formula
alkylene
cycloalkyl
Prior art date
Application number
PCT/EP2007/002637
Other languages
French (fr)
Inventor
Gerhard Zoller
Stefan Petry
Markus Follmann
Günter Müller
Norbert Tennagels
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to JP2009501922A priority Critical patent/JP2009531356A/en
Priority to AU2007229708A priority patent/AU2007229708A1/en
Priority to BRPI0709211-3A priority patent/BRPI0709211A2/en
Priority to EP07723584A priority patent/EP2001878B1/en
Priority to AT07723584T priority patent/ATE528307T1/en
Priority to CA002647422A priority patent/CA2647422A1/en
Priority to MX2008012126A priority patent/MX2008012126A/en
Publication of WO2007110215A1 publication Critical patent/WO2007110215A1/en
Priority to US12/235,053 priority patent/US7897616B2/en
Priority to NO20084419A priority patent/NO20084419L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to imidazopyridin-2-one derivatives of the formula I, to their pharmaceutically usable salts and to their use as medicaments.
  • the invention provides imidazopyridin-2-one derivatives of the formula I
  • R1 , R1 ' are the same or different and are each (C 5 -Ci 6 )-alkyl, (C 5 -Ci 2 )-cycloalkyl, (CrC ⁇ -alkylenearyl, (CrC-O-alkyleneheteroaryl, (Ci-C 4 )-alkylene-(C 5 - Ci 2 )-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (d-C 6 )-alkyl, (C- I -C ⁇ )- alkyloxy, hydroxyl, (CrC ⁇ J-alkylmercapto, amino, (Ci-C 6 )-alkylamino, di- (C 2 -Ci2)-alkylamino, mono-(Ci-C6)-alkylaminocarbonyl, di-(C2-C ⁇ )- alkylamin
  • R1 " is (Ci-Ci ⁇ )-alkyl, (C 5 -C 12 )-cycloalkyl, (C r C 4 )-alkylenearyl, (Ci-C 4 )- alkyleneheteroaryl, (Ci-C 4 )-alkylene-(C 5 -Ci 2 )-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (C r C 6 )-alkyl, (Ci-C 6 )-alkyloxy, hydroxyl, (C 1 -C 6 )- alkylmercapto, amino, (Ci-C ⁇ J-alkylamino, di-(C 2 -C 12 )-alkylamino, mono- (Ci-C 6 )-alkylaminocarbonyl, di-(C 2 -C 8 )-alkylaminocarbony
  • R2 is hydrogen
  • R3 is the same or different and is hydrogen, (C-i-C ⁇ J-alkyl, benzyl;
  • R4, R5 are the same or different and are each hydrogen, (Ci-C 6 )-alkyl, aryl, (C 3 -
  • R6 is hydrogen, (Ci-C- ⁇ o)-alkyl, (Ci-C 4 )-alkylenearyl, (C-,-C 4 )-alkylene- heterocycle, (Ci-C 4 )-alkylene-(C 3 -Ci 2 )-cycloalkyl, bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C 6 )-alkyl, (CrC ⁇ J-alkyloxy, hydroxy, (C-i-C ⁇ )- alkylmercapto, amino, (Ci-C 6 )-alkylamino, di-(C 2 -Ci 2 )-alkylamino, mono-
  • R6 is not (Ci-C 4 )-alkylenearyl, (C 1 -C 4 )- alkylene-heterocycle, (Ci-C 4 )-alkylene-(C 3 -Ci 2 )-cycloalkyl or bicycle;
  • R is the same or different and is hydrogen, halogen, (Ci-C 6 )-alkyl, hydroxyl, phenoxy, trifluoromethyl, COOR3, pentafluorosulfanyl, amino, (Ci-C ⁇ )- alkylamino, di-(C 2 -C 8 )-alkylamino, (CrC 6 )-alkylsulfonyl, aminosulfonyl, phenyl, (C 5 -C 7 )-heterocycle, (Ci-C 6 )-alkylcarbonyl, CO-NR4R5, O-CO- NR4R5, O-CO-(C 1 -C 6 )-alkylene-CO-O-(Ci-C 6 )-alkyl, 0-CO-(CrC 6 )- alkylene-CO-NR4R5 or unsubstituted or mono- or poly-F-substituted (d-
  • R1 , R1 ' are the same or different and are each (C 6 -Ci2)-alkyl, (Ci-C 3 )- alkylenearyl, (Ci-C 3 )-alkylene-heterocycle, (C r C 3 )-alkylene-(C 5 -Ci2)- cycloalkyl, (C 8 -Ci 4 )-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrC 6 )-alkyl, (CrC 3 )-alkyloxy, hydroxyl, amino, (Ci-C 6 )-alkylamino, (C I -C ⁇ )- alkyloxycarbonyl, (Ci-C ⁇ J-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
  • R1 " is (Ci-Ci 2 )-alkyl, (Ci-C 3 )-alkylenearyl, (Ci-C 3 )-alkylene-heterocycle,
  • R2 is hydrogen
  • R3 is hydrogen, (Ci-C 6 )-alkyl, benzyl;
  • R4, R5 are the same or different and are each hydrogen, (Ci-C ⁇ J-alkyI, (C 3 -Ci 2 )- cycloalkyl, phenyl, (Ci-C 4 )-alkylenephenyl, (Ci-C 4 )-alkylene-(C 4 -C 12 )- cycloalkyl;
  • R6 is hydrogen, (C-i-Cio)-alkyl, (Ci-C 4 )-alkylene-phenyl, (C r C 4 )-alkylene- heterocycle, (Ci-C 4 )-alkylene-(C 3 -Ci2)-cylcoalkyl, where phenyl, heterocycle, cycloalkyl may be mono- or polysubstituted preferably by halogen, (C r C 6 )-alkyl, (Ci-C 3 )-alkyloxy, hydroxyl, (C 1 -C 6 )- alkoxycarbonyl, (Ci-C 6 )-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (Ci-C 6 )-alkylsulfonyl; or
  • R is the same or different and is hydrogen, halogen, (CrC 6 )-alkyl, trifluoromethyl, hydroxyl, amino, (C r C 6 )-alkylcarbonyl, COOR3, (CrC 6 )- alkylsulfonyl, pentafluorosulfanyl, or unsubstituted or mono- or poly-F- substituted (C-i-C3)-alkyloxy;
  • R1 , RT are the same or different and are each (C 6 -Ci O )-alkyl, -CH 2 -phenyl, (Ci- C 2 )-alkyleneheteroaryl or bicycle of the formula Ic
  • phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (Ci-C 6 )-alkyl, (Ci-C 6 )-alkyloxy, hydroxyl, amino, (C-i-C 6 )-alkoxycarbonyl, (Ci-C 6 )-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
  • R1 " is (C- ⁇ -Cio)-alkyl, -CH 2 -phenyl, (CrC 2 )-alkyleneheteroaryl or bicycle of the formula Ic
  • phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (CrC 6 )-alkyl, (Ci-C 6 )-alkyloxy, hydroxyl, amino, (C-i-C ⁇ J-alkoxycarbonyl, (Ci-C 6 )-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy; R2 is hydrogen;
  • R3 is hydrogen, (CrC 6 )-alkyl
  • R is the same or different and is hydrogen, halogen, hydroxyl, (Ci-C ⁇ )- alkyloxy, trifluoromethyl, (Ci-C ⁇ J-alkylcarbonyl or (Ci-C ⁇ J-alkyl;
  • R1 " is (CrCio)-alkyl, -CH2-phenyl or bicycle of the formula Ic
  • R2 is hydrogen
  • R6 is hydrogen, (Ci-C 4 )-alkyl, CH 2 -phenyl, where phenyl may be mono- or polysubstituted by halogen, (C-i-C 6 )-alkyl, (Ci-C 3 )-alkyloxy, hydroxyl, (C r C 6 )-alkylcarbonyl, trifluoromethyl; or
  • the invention relates to compounds of the formula I in the form of their salts, racemates, racemic mixtures and pure enantiomers, and also to their diastereomers and mixtures thereof.
  • alkyl or alkylene radicals in the substituents R, R1 , R1 ' , R1 " , R2, R3, R4, R5 and R6 may be either straight-chain or branched.
  • Halogen is fluorine, chlorine, bromine or iodine, particularly fluorine or chlorine.
  • Haloalkyl is an alkyl substituted singly, multiply or fully by halogen.
  • Preferred halogens are fluorine and chlorine.
  • a cycloalkyl radical is understood to mean a ring system which comprises one or more rings and is saturated or partially unsaturated (with one or two double bonds), which is composed exclusively of carbon atoms, for example cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl or adamantyl.
  • the cycloalkyl radicals may be mono- or polysubstituted by suitable groups, for example F, Cl, Br, I 1 CF 3 , NO 2 , N 3 , CN, COOH, COO(Ci-C 6 )alkyl, CONH 2 , CONH(C 1 - R is the same or different and is hydrogen, methyl;
  • R1 , R1 ' are the same or different and are each (C 6 -Cio)-alkyl, -CH 2 -phenyl or bicycle of the formula Id
  • R2 is hydrogen
  • R6 is hydrogen, methyl, or
  • W is -(SO 2 )-.
  • R6 is hydrogen, (Ci-C4)-alkyl, (Ci-C 4 )-alkylenearyl, preferably hydrogen or (Ci-C 4 )-alkyl, more preferably hydrogen, methyl, ethyl, n-propyl or n- butyl, most preferably hydrogen or methyl; where aryl may be mono- or polysubstituted preferably by halogen, (C 1 - C 6 )-alkyl, (CrC ⁇ J-alkyloxy, hydroxyl, (Ci-C 6 )-alkylmercapto, amino, (d- C 6 )alkyl, CON[(C r C 6 )alkyl] 2 , cycloalkyl, (C r Ci 0 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O-(C r C 6 )-alkyl, O-CO-(
  • Bicycle is a partly unsaturated bicyclic ring system which has from 8 to 14 ring members and has exclusively carbon atoms as ring members. Ring systems which contain a fused benzene ring are included in this definition. Mention is made by way of example of the tetrahydronaphthyl, alpha- or beta-tetralonyl, indanyl or indan-1-onyl radical. Preferred bicycle radicals are tetrahydronaphthyl and indanyl.
  • the bicycle radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl 1 Br 1 I, CF 3 , NO 2 , N 3 , CN, COOH, COO(C r C 6 )alkyl, CONH 2 , CONH(Ci-C 6 )alkyl, CON[(Ci-C 6 )alkyl] 2 , cycloalkyl, (CrC 10 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, 0-(C 1 - C 6 )-alkyl, O-CO-(Ci-C 6 )-alkyl, O-CO-(Ci-C 6 )-aryl, O-CO-(C r C 6 )-heterocycle; PO 3 H 2 , SO 3 H, SO 2 -NH 2 , SO 2 NH(Ci-C 6 )-alkyl, SO 2 N
  • aryl radical is understood to mean a phenyl or naphthyl radical.
  • the aryl radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br, I, CF 3 , NO 2 , CN, COOH, COO(d-C 6 )alkyl, CONH 2 , CONH(C r C 6 )alkyl, CON[(d-C 6 )alkyl] 2, , (C 3 -Ci 0 )-cycloalkyl, (d-C 10 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )- alkynyl, O-(Ci-C 6 )-alkyl, O-CO-(Ci-C 6 )-alkyl, O-CO-(CrC 6 )-aryl,
  • Heterocycle is a mono- or bicyclic ring system having from 5 to 12 ring members, in which at least one atom in the ring system is a heteroatom selected from the group consisting of N, O and S. This definition also includes ring systems in which the heterocycle is fused to a benzene ring.
  • (C 5 -C 7 )-Heterocycle is a monocyclic ring system;
  • (C 8 -Ci 2 )-heterocycle is a bicyclic ring system.
  • Suitable "heterocyclic rings” or “heterocyclic radicals” are azocinyl, benzimidazolyl, benzofuryl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH- carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1 ,5,2- dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuryl, furyl, furazanyl, imidazolidinyl,
  • Pyridyl is any of 2-, 3- or 4-pyridyl.
  • Thienyl is either 2- or 3-thienyl.
  • Furyl is either 2- or 3-furyl.
  • N-oxides of these compounds for example 1-oxy- 2-, -3- or -4-pyridyl.
  • heterocyclic rings or heterocyclic radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br 1 I 1 CF 3 , NO 2 , N 3 , CN, COOH 1 COO(Ci-C 6 )alkyl, CONH 2 , CONH(Ci-C 6 )alkyl, CON[(Ci-C 6 )alkyl] 2 , (d-C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )- alkynyl, O-(Ci-C 6 )-alkyl, where one, more than one or all hydrogen(s) in the alkyl radicals may be replaced by fluorine; PO 3 H 2 , SO 3 H, SO 2 -NH 2 , SO 2 NH(C r C 6 )-alkyl, SO 2 N[(C r C 6 )-alkyl] 2 , S-(CrC 6 )
  • Heteroaryl is a mono- or bicyclic aromatic ring system having from 5 to 12 ring members, in which at least one atom in the ring system is a heteroatom selected from the group consisting of N 1 O and S. This definition also includes ring systems in which the heteroaryl is fused to a benzene ring.
  • Suitable "heteroaryl rings” or “heteroaryl radicals” are, for example, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, furyl, furazanyl, imidazolyl, 1 H-indazolyl, indolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5- oxadiazolyl, 1 ,3,4-oxadiazolyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, thiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,5-thi
  • Preferred heteroaryl radicals are benzothiophenyl and thiophenyl.
  • the heteroaryl rings or heteroaryl radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br, I 1 CF 3 , NO 2 , N 3 , CN, COOH, COO(C r C 6 )alkyl, CONH 2 , CONH(Ci-C 6 )alkyl, CON[(CrC 6 )alkyl] 2 , (Ci-C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O-(Ci-C 6 )-alkyl, where one, more than one or all hydrogen(s) in the alkyl radicals may be replaced by fluorine; PO 3 H 2 , SO 3 H, SO 2 -NH 2 , SO 2 NH(CrC 6 )-alkyl, SO 2 N[
  • Suitable pharmaceutically acceptable salts of the inventive compounds are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and organic acids, for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid and tartaric acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid
  • organic acids for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glyco
  • Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts) and salts of trometamol (2-amino-2- hydroxymethyl-1 ,3-propanediol), diethanolamine, lysine or ethylenediamine.
  • Salts with a pharmaceutically unacceptable anion are likewise included in the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for the use in non-therapeutic, for example in vitro, applications.
  • physiologically functional derivative refers to any physiologically compatible derivative of an inventive compound of the formula I 1 for example an ester which, on administration to a mammal, for example the human, is capable (directly or indirectly) of forming a compound of the formula I or an active metabolite thereof.
  • the physiologically functional derivatives also include prodrugs of the inventive compounds, as described, for example, in H. Okada et al., Chem. Pharm. Bull., 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to give an inventive compound. These prodrugs may themselves be active or not.
  • inventive compounds may also be present in various polymorphic forms, for example as amorphous and crystalline polymorphic forms. All polymorphic forms of the inventive compounds are included within the scope of the invention and are a further aspect of the invention.
  • R1 , RT are the same or different and are each (C 5 -Ci 6 )-alkyl, (C 5 -Ci 2 )-cycloalkyl, (CrC 4 )-alkylenearyl, (Ci-C 4 )-alkyleneheteroaryl, (Ci-C 4 )-alkylene-(Cs-
  • R1 " is (Ci-Ci 6 )-alkyl, (C 5 -C 12 )-cycloalkyl, (Ci-C 4 )-alkylenearyl, (C 1 -C 4 )- alkyleneheteroaryl, (Ci-C 4 )-alkylene-(C 5 -Ci 2 )-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C 6 )-alkyl, (CrC 6 )-alkyloxy, hydroxyl, (CrC 6 )- alkylmercapto, amino, (Ci-C 6 )-alkylamino, di-(C 2 -Ci 2 )-alkylamino, mono- (Ci-C 6 )-alkylaminocarbonyl, di-(C 2 -C 8 )-alkylaminocarbon
  • R2 is hydrogen
  • R3 is the same or different and is hydrogen, (Ci-C 6 )-alkyl, benzyl;
  • R4, R5 are the same or different and are each hydrogen, (CrC 6 )-alkyl, aryl, (C 3 -
  • Ci 2 -cycloalkyl, (C r C 4 )-alkylenearyl, (C 1 -C 3 )-alkylene-(C 3 -C 12 )-cycloalkyl;
  • R6 is hydrogen, (Ci-C- ⁇ O )-alkyl, (CrC 4 )-alkylenearyl, (CrC 4 )-alkylene- heterocycle, (Ci-C 4 )-alkylene-(C 3 -C 12 )-cycloalkyl, (C 8 -Ci 4 )-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C 6 )-alkyl, (CrC 6 )-alkyloxy, hydroxyl, (C 1 -C 6 )- alkylmercapto, amino, (Ci-C 6 )-alkylamino, di-(C 2 -Ci2)-alkylamino, mono-
  • (Ci-C 6 )-alkylaminocarbonyl di-(C 2 -C 8 )-alkylaminocarbonyl, (Ci-C 6 )- alkoxycarbonyl, (CrC 6 )-alkylcarbonyl, trifluoromethyl, trifluoromethyloxy, cyano, (Ci-C 6 )-alkylsulfonyl, aminosulfonyl; or
  • HDL endothelial lipase
  • a lowering of the HDL level leads to the progression of atherosclerosis and its sequelae such as coronary heart disease and additionally promotes the development of metabolic syndrome and its sequela of diabetes.
  • An inhibition of the EL should thus lead generally to the prevention of atherosclerotic disorders and indirectly reduce the probability of illness in persons with an increased risk of diabetes.
  • the compounds of the formula I are notable for exhibiting an improved solubility compared with compounds of similar structure in aqeous media with at least the same time high activity.
  • Preferred compounds of the invention further exhibit an improved metabolic stability compared with compounds of the prior art.
  • Such compounds are particularly suitable for the treatment and/or prevention of
  • Dyslipidemias and general impairments of lipid metabolism and their sequelae for example atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following factors:
  • diabetes mellitus in particular type 2 diabetes, including the prevention of the sequelae associated therewith (hyperglycemia, glucose intolerance, loss of pancreatic ⁇ cells, macro- and microvascular disorders
  • - atherosclerosis for example (but not restricted thereto) coronary sclerosis, including angina pectoris or myocardial infarction, stroke
  • - solid tumors and neoplasms for example (but not restricted thereto) carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidney and the urinary tract, of the genital tract, prostate carcinomas, etc.
  • dermatitis for example seborrheic dermatitis or photodermatitis
  • keratitis and keratoses for example seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or keratosis follicularis
  • HPV human papilloma viral infections
  • venereal papillomata for example venereal papillomata
  • viral warts for example molluscum contagiosum
  • leukoplakia - papular dermatoses for example lichen planus
  • - skin cancer for example basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas
  • PCOS polycystic ovary syndrome
  • osteoarthritis - lupus erythematosus (LE) or inflammatory rheumatic disorders, for example rheumatoid arthritis
  • ARDS acute respiratory distress syndrome
  • the amount of an inventive compound which is required in order to achieve the desired biological effect is dependent upon a series of factors, for example the specific compound selected, the intended use, the mode of administration and the clinical condition of the patient.
  • the daily dose is generally in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3- 10 mg/kg/day.
  • An intravenous dose may, for example, be in the range from 0.3 mg to 1.0 mg/kg and may suitably be administered as an infusion of from 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for these purposes may, for example, contain from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter.
  • Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
  • Ampoules for injections may therefore contain, for example, from 1 mg to 100 mg, and single dose formulations which can be administered orally, for example tablets or capsules, may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg.
  • the compounds of the formula I may be used for therapy of the abovementioned conditions as the compounds themselves, although they are preferably in the form of a pharmaceutical composition with an acceptable carrier.
  • the carrier of course has to be acceptable, in the sense that it is compatible with the other constituents of the composition and is not damaging to the health of the patient.
  • the carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05 to 95% by weight of the active ingredient.
  • Further pharmaceutically active substances may likewise be present, including further inventive compounds.
  • the inventive pharmaceutical compositions may be produced by one of the known pharmaceutical methods which consist essentially in mixing the constituents with pharmacologically acceptable carriers and/or excipients.
  • compositions are those which are suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the type of the compound of formula I used in each case.
  • Coated formulations and coated slow-release formulations are also encompassed by the scope of the invention. Preference is given to acid- and gastric fluid-resistant formulations. Suitable gastric fluid-resistant coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
  • Suitable pharmaceutical preparations for oral administration may be in the form of separate units, for example capsules, cachets, lozenges or tablets, each of which contains a certain amount of the compound of the formula I; as powder or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional constituents) are brought into contact.
  • the compositions are prepared by uniform and homogeneous mixing of the active ingredient with a liquid carrier and/or finely divided solid carrier, after which the product is shaped if necessary.
  • a tablet can thus be produced by compressing or shaping a powder or granules of the compound, optionally with one or more additional constituents.
  • Compressed tablets can be prepared by tableting the compound in free-flowing form, for example a powder or granules, optionally mixed with a binder, lubricant, inert diluent and/or one (or more) surfactants/dispersants in a suitable machine.
  • Shaped tablets can be prepared by shaping the pulverulent compound moistened with an inert liquid diluent in a suitable machine.
  • compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound of formula I with a flavoring, customarily sucrose, and gum arabic or tragacanth, and pastilles which include the compound in an inert base, such as gelatin and glycerol or sucrose and gum arabic.
  • Suitable pharmaceutical compositions for parenteral administration include preferably sterile aqueous preparations of a compound of the formula I which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations can preferably be produced by mixing the compound with water and making the solution obtained sterile and isotonic with the blood.
  • Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound.
  • Suitable pharmaceutical compositions for rectal administration are preferably in the form of single dose suppositories. These can be prepared by mixing a compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
  • Suitable pharmaceutical compositions for topical application on the skin are preferably in the form of an ointment, cream, lotion, paste, spray, aerosol or oil.
  • Useful carriers include petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
  • the active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, preferably from 0.5 to 2%.
  • Suitable pharmaceutical compositions for transdermal applications may be in the form of single plasters which are suitable for long-term close contact with the epidermis of the patient.
  • Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer.
  • a suitable active ingredient concentration is from approx. 1 % to 35%, preferably from approx. 3% to 15%.
  • a particular means of releasing the active ingredient may be by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
  • the compounds of the formula I are notable for favorable effects on disorders of lipid metabolism. They positively influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes.
  • the compounds of the invention can be administered alone or in combination with one or more further pharmacologically active ingredients.
  • the compounds of the invention can be administered with active ingredients which have a similar pharmacological effect to themselves.
  • they can be administered in combination with active ingredients which have favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are
  • active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and
  • active ingredients for the treatment of neurodegenerative diseases 11. active ingredients for the treatment of neurodegenerative diseases 12. active ingredients for the treatment of diseases of the central nervous system 13. active ingredients for the treatment of dependence on drugs, nicotine and alcohol 14. analgesics
  • Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
  • active ingredients particularly suitable for the combination products are: All antidiabetics which are mentioned in the Rote Liste 2006, chapter 12; all weight- reducing agents/appetite suppressants which are mentioned in the Rote Liste 2006, chapter 1 ; all lipid-lowering agents which are mentioned in the Rote Liste 2006, chapter 58. They can be combined with the compound of the invention of the formula I in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients mentioned hereinafter are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
  • Antidiabetics include insulin and insulin derivatives such as, for example, Lantus ® (see www.lantus.com) or HMR 1964 or those described in WO 2005/005477 (Novo Nordisk), fast-acting insulins (see US 6,221 ,633), inhalable insulins such as, for example, Exubera ® or oral insulins such as, for example, IN-105 (Nobex) or Oral-lynTM (Generex Biotechnology), GLP-1 -derivatives such as, for example, exenatide, liraglutide or those which have been disclosed in WO 98/08871 or WO 2005/027978 of Novo Nordisk A/S, in WO 01/04156 of Zealand or in WO 00/34331 of Beaufour-lpsen, Pramlintide Acetate (Symlin; Amylin Pharmaceuticals), and orally effective hypoglycemic active ingredients.
  • inhalable insulins such as, for example, Exubera ® or oral insulin
  • the active ingredients include preferably sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, inhibitors of glycogen phosphorylase, glucagon antagonists, glucokinase activators, inhibitors of fructose-1 ,6-bisphosphatase, modulators of glucose transporter 4 (GLUT4), inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT),
  • GLP-1 agonists such as, for example, those which have been disclosed in
  • WO 97/26265 and WO 99/03861 of Novo Nordisk A/S inhibitors of dipeptidylpeptidase IV (DPP-IV), insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenosis, modulators of glucose uptake, of glucose transport and of glucose reabsorption, inhibitors of 11 ⁇ -HSD1 , inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), compounds which alter lipid metabolism such as antihyperlipidemic active ingredients and antilipidemic active ingredients, compounds which reduce food intake, compounds which increase thermogenesis,
  • DPP-IV dipeptidylpeptidase IV
  • insulin sensitizers inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenosis
  • modulators of glucose uptake of glucose transport and of glucose reabsorption
  • the compound of the formula I is administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
  • an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
  • the compound of the formula I is administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO 2005/042692), MD-0727 (Microbia Inc., WO 2005/021497) or with compounds as described in WO 2002/066464 (Kotobuki Pharmaceutical Co. Ltd.), WO 2005/062824 (Merck & Co.) or WO 2005/061451 and WO 2005/061452 (AstraZeneca AB).
  • a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO 2005/042692), MD-0727 (Microbia Inc., WO 2005/021497) or with compounds as described in WO 2002/06
  • the compound of the formula I is administered in combination with a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483 or CS-011 (rivoglitazone).
  • a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483 or CS-011 (rivoglitazone).
  • the compound of the formula I is administered in combination with a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 or DRF-10945.
  • a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 or DRF-10945.
  • the compound of the formula I is administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, muraglitazar, tesaglitazar, naveglitazar, LY-510929, ONO-5129, E-3030 or as described in WO 00/64888, WO 00/64876, WO 03/020269, WO 2004/075891 , WO 2004/076402, WO 2004/075815, WO 2004/076447, WO 2004/076428, WO 2004/076401 , WO 2004/076426, WO 2004/076427, WO 2006/018118, WO 2006/018115, and WO 2006/018116 or in J.
  • a mixed PPAR alpha/gamma agonist such as, for example, muraglitazar, tesaglitazar, naveglitazar, LY-510929, ONO-5129, E-3030 or as described in WO 00/64
  • the compound of the formula I is administered in combination with a PPAR delta agonist such as, for example, GW-501516, or as described in WO 2005/097762, WO 2005/097786, WO2005/097763, WO 2006/029699.
  • a PPAR delta agonist such as, for example, GW-501516, or as described in WO 2005/097762, WO 2005/097786, WO2005/097763, WO 2006/029699.
  • the compound of the formula I is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
  • the compound of the formula I is administered in combination with a fibrate such as, for example, fenofibrate, clofibrate or bezafibrate.
  • the compound of the formula I is administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757 or those described in WO 2005/085226.
  • an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757 or those described in WO 2005/085226.
  • the compound of the formula I is administered in combination with a CETP inhibitor such as, for example, torcetrapib or JTT-705.
  • the compound of the formula I is administered in combination with a bile acid absorption inhibitor (see, for example, US 6,245,744, US 6,221 ,897 or WO 00/61568), such as, for example, HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9.
  • a bile acid absorption inhibitor see, for example, US 6,245,744, US 6,221 ,897 or WO 00/61568
  • HMR 1741 such as, for example, HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9.
  • the compound of the formula I is administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine or colesevelam.
  • a polymeric bile acid adsorbent such as, for example, cholestyramine or colesevelam.
  • the compound of the formula I is administered in combination with an LDL receptor inducer (see US 6,342,512), such as, for example, HMR1171 , HMR1586 or those as described in WO 2005/097738.
  • an LDL receptor inducer see US 6,342,512
  • the compound of the formula I is administered in combination with Omacor® (Omega-3 fatty acids; highly concentrated ethyl esters of eicosapentaenoic acid and of docosahexaenoic acid).
  • the compound of the formula I is administered in combination with an ACAT inhibitor such as, for example, avasimibe.
  • the compound of the formula I is administered in combination with an antioxidant such as, for example, OPC-14117, probucol, tocopherol, ascorbic acid, ⁇ -carotene or selenium.
  • an antioxidant such as, for example, OPC-14117, probucol, tocopherol, ascorbic acid, ⁇ -carotene or selenium.
  • the compound of the formula I is administered in combination with a vitamin such as, for example, vitamin B6 or vitamin B12.
  • the compound of the formula I is administered in combination with a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
  • a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
  • the compound of the formula I is administered in combination with an ATP citrate lyase inhibitor such as, for example, SB-204990.
  • the compound of the formula I is administered in combination with a squalene synthetase inhibitor such as, for example, BMS-188494 or as described in WO 2005/077907.
  • a squalene synthetase inhibitor such as, for example, BMS-188494 or as described in WO 2005/077907.
  • the compound of the formula I is administered in combination with a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027).
  • a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027).
  • the compound of the formula I is administered in combination with an HM74A receptor agonist such as, for example, nicotinic acid.
  • the compound of the formula I is administered in combination with a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
  • a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
  • the compound of the formula I is administered in combination with insulin.
  • the compound of the formula I is administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
  • a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
  • the compound of the formula I is administered in combination with a biguanide such as, for example, metformin.
  • a biguanide such as, for example, metformin.
  • the compound of the formula I is administered in combination with a meglitinide such as, for example, repaglinide or nateglinide.
  • a meglitinide such as, for example, repaglinide or nateglinide.
  • the compound of the formula I is administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2- quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
  • a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2- quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione
  • the compound of the formula I is administered in combination with an ⁇ -glucosidase inhibitor such as, for example, miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor such as, for example, miglitol or acarbose.
  • the compound of the formula I is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
  • the compound of the formula I is administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
  • the compound of the formula I is administered in combination with an inhibitor of glycogen phosphorylase, such as, for example, PSN- 357 or FR-258900 or those as described in WO 2003/084922, WO 2004/007455, WO 2005/073229-31 or WO 2005/067932.
  • an inhibitor of glycogen phosphorylase such as, for example, PSN- 357 or FR-258900 or those as described in WO 2003/084922, WO 2004/007455, WO 2005/073229-31 or WO 2005/067932.
  • the compound of the formula I is administered in combination with glucagon receptor antagonists such as, for example, A-770077, NNC-25-2504 or as described in WO 2004/100875 or WO 2005/065680.
  • glucagon receptor antagonists such as, for example, A-770077, NNC-25-2504 or as described in WO 2004/100875 or WO 2005/065680.
  • the compound of the formula I is administered in combination with activators of glucokinase, such as, for example, RO-4389620, LY- 2121260 (WO 2004/063179), PSN-105, PSN-110, GKA-50 or those as are described for example by Prosidion in WO 2004/072031 , WO 2004/072066, WO 05/103021 or WO 06/016178, by Roche in WO 00/058293, WO 00/183465, WO 00/183478, WO 00/185706, WO 00/185707, WO 01/044216, GB 02385328, WO 02/008209, WO 02/014312, WO 02/46173, WO 02/48106, DE 10259786, WO 03/095438, US 04067939 or WO 04/052869, by Novo Nordisk in EP 1532980, WO 03/055482, WO 04/002481
  • the compound of the formula I is administered in combination with inhibitors of fructose-1 ,6-bisphosphatase (FBPase), such as, for example, CS-917.
  • FBPase fructose-1 ,6-bisphosphatase
  • the compound of the formula I is administered in combination with modulators of glucose transporter 4 (GLUT4), such as, for example, KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004)).
  • GLUT4 glucose transporter 4
  • the compound of the formula I is administered in combination with inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), as are described for example in WO 2004/101528.
  • GFAT glutamine-fructose-6-phosphate amidotransferase
  • the compound of the formula I is administered in combination with inhibitors of dipeptidylpeptidase IV (DPP-IV), such as, for example, vildagliptin (LAF-237), sitagliptin (MK-0431), saxagliptin (BMS-477118), GSK-823093, PSN-9301 , SYR-322, SYR-619, TA-6666, TS-021 , GRC-8200, GW-825964X or as are described in WO 2003/074500, WO 2003/106456, WO 2004/50658, WO 2005/058901 , WO 2005/012312, WO 2005/012308, PCT/EP2005/007821 , PCT/EP2005/008005, PCT/EP2005/008002, PCT/EP2005/008004, PCT/EP2005/008283, DE 10 2005 012874.2 or DE 10 2005 012873.4.
  • DPP-IV dipeptidylpeptidase
  • the compound of the formula I is administered in combination with inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11 ⁇ -HSD1 ), such as, for example, BVT-2733 or those as are described for example in WO 2001/90090-94, WO 2003/43999, WO 2004/112782, WO 2003/44000, WO 2003/44009, WO 2004/112779, WO 2004/113310, WO 2004/103980, WO 2004/112784, WO 2003/065983, WO 2003/104207, WO 2003/104208, WO 2004/106294, WO 2004/01 1410, WO 2004/033427, WO 2004/041264, WO 2004/037251 , WO 2004/056744, WO 2004/065351 , WO 2004/089367, WO 2004/089380, WO 2004/089470-71 , WO 2004/089896, WO 2005/016877 or WO 2005/
  • the compound of the formula I is administered in combination with inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), as are described for example in WO 2001/19830-31 , WO 2001/17516, WO 2004/506446, WO 2005/012295, PCT/EP2005/005311 , PCT/EP2005/005321 , PCT/EP2005/007151 , PCT/EP2005/01294 or DE 10 2004 060542.4.
  • PTP1 B protein tyrosine phosphatase 1 B
  • the compound of the formula I is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), such as, for example, KGA-2727, T-1095 and SGL-0010 or as are described for example in WO 2004/007517, WO 2004/52903, WO 2004/52902, WO 2005/121161 , WO 2005/085237, JP2004359630 or by A. L. Handlon in Expert Opin. Ther. Patents (2005) 15(11), 1531-1540.
  • modulators of the sodium-dependent glucose transporter 1 or 2 SGLT1 , SGLT2
  • the compound of the formula I is administered in combination with inhibitors of hormone-sensitive lipase (HSL) as described for example in WO 01/17981 , WO 01/66531 , WO 2004/035550, WO 2005/073199 or WO 03/051842.
  • HSL hormone-sensitive lipase
  • the compound of the formula I is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC), such as, for example, those as described in WO 1999/46262, WO 2003/72197, WO 2003/072197 or WO 2005/044814.
  • ACC acetyl-CoA carboxylase
  • the compound of the formula I is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), such as, for example, those as described in WO 2004/074288.
  • PPCK phosphoenolpyruvate carboxykinase
  • the compound of the formula I is administered in combination with an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta), as described for example in US2005222220, WO 2004/046117, WO 2005/085230, WO 2005/111018, WO 2003/078403, WO 2004/022544, WO 2003/106410, WO 2005/058908, US2005038023, WO 2005/009997, US2005026984, WO 2005/000836, WO 2004/106343, EP1460075, WO 2004/014910, WO 2003/076442, WO 2005/087727 or WO 2004/046117.
  • PPCK phosphoenolpyruvate
  • the compound of the formula I is administered in combination with an inhibitor of protein kinase C beta (PKC beta), such as, for example, ruboxistaurin.
  • PLC beta protein kinase C beta
  • the compound of the formula I is administered in combination with an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
  • an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
  • the compound of the formula I is administered in combination with inhibitors of "l-kappaB kinase" (IKK inhibitors), as are described for example in WO 2001/000610, WO 2001/030774, WO 2004/022553 or WO 2005/097129.
  • IKK inhibitors inhibitors of "l-kappaB kinase”
  • the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor, like those described for example in WO 2005/090336.
  • the compound of the formula I is administered in combination with CART modulators (see “Cocaine-amphetamine- regulated transcript influences energy metabolism, anxiety and gastric emptying in mice” Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558); NPY antagonists such as, for example, naphthalene-1 -sulfonic acid ⁇ 4-[(4-amino- quinazolin-2-ylamino)methyl]cyclohexylmethyl ⁇ amide hydrochloride (CGP 71683A); peptide YY 3-36 (PYY3-36) or analogous compounds, such as, for example, CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34), CJC-1643 (derivative of PYY3-36 which conjugates in vivo to serum albumin) or those as are described in WO 2005/080424; cannabinoid receptor 1 antagonists
  • MC4 agonists e.g. 1-amino-1 ,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2-(3a- benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4- chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)) or LB53280, LB53279, LB53278 or THIQ, MB243, RY764, CHIR-785, PT-141 or those as are described in WO 2005/060985, WO 2005/009950, WO 2004/087159, WO 2004/078717, WO 2004/078716, WO 2004/024720, US20050124652, WO 2005/051391 , WO 2004/112793, WOUS20050222014, US20050176728, US200501649
  • WO 2004/072077 or WO 2006/024390 orexin receptor antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3-[1 ,5]naphthyridin-4- ylurea hydrochloride (SB-334867-A) or those as are described for example in WO 2001/96302, WO 2001/85693, WO 2004/085403 or WO 2005/075458); histamine H3 receptor agonists (e.g.
  • CRF antagonists e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1 ,3,9-triazafluoroen-4- yl]dipropylamine (WO 00/66585));
  • CRF BP antagonists e.g. urocortin
  • urocortin agonists urocortin agonists
  • ⁇ 3 agonists such as, for example, 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-
  • MCH (melanin-concentrating hormone) receptor antagonists such as, for example,
  • CCK-A agonists such as, for example, ⁇ 2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2- cyclohexylethyOthiazol ⁇ -ylcarbamoyll- ⁇ J-dirnethylindol-i -yljacetic acid trifluoroacetic acid salt (WO 99/15525), SR-146131 (WO 0244150) or SSR-125180); serotonin reuptake inhibitors (e.g. dexfenfluramine); mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549);
  • 5-HT receptor agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO
  • 5-HT2C receptor agonists such as, for example, APD-356, BVT-933 or those as are described in WO 2000/77010, WO 2007/7001-02, WO 2005/019180,
  • 5-HT6 receptor antagonists as are described for example in WO 2005/058858; bombesin receptor agonists (BRS-3 agonists); galanin receptor antagonists; growth hormone (e.g. human growth hormone or AOD-9604); growth hormone releasing compounds (tertiary butyl 6-benzyloxy-1-(2-diisopropyl- aminoethylcarbamoyl)-3,4-dihydro-1 H-isoquinoline-2-carboxylate (WO 01/85695)); growth hormone secretagogue receptor antagonists (ghrelin antagonists) such as, for example, A-778193 or those as are described in WO 2005/030734;
  • growth hormone secretagogue receptor antagonists ghrelin antagonists
  • TRH agonists see, for example, EP 0 462 884
  • uncoupling protein 2 or 3 modulators include leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C; Rozhavskaya- Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881);
  • DA agonists bromocriptine or Doprexin
  • lipase/amylase inhibitors like those described for example in WO 00/40569
  • DGATs diacylglycerol O-acyltransferases
  • the further active ingredient is leptin; see, for example, "Perspectives in the therapeutic use of leptin", Salvador, Javier; Gomez- Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622.
  • the further active ingredient is dexamphetamine or amphetamine.
  • the further active ingredient is fenfluramine or dexfenfluramine.
  • the further active ingredient is sibutramine.
  • the further active ingredient is mazindole or phentermine.
  • the compound of the formula I is administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, Carob/Caromax® (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6)).
  • Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, lndustriepark Hoechst, 65926 Frankfurt/Main. Combination with Caromax® is possible in one preparation or by separate administration of compounds of the formula I and Caromax®.
  • Caromax® can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
  • the compound of the formula I is administered in combination with PDE inhibitors (phosphodiesterase), like those described for example in WO 2003/077949 or WO 2005/012485.
  • PDE inhibitors phosphodiesterase
  • NAR-1 neurotinic acid receptor
  • the compound of the formula I is administered in combination with CB2 (cannabinoid receptor) agonists like those described for example in US2005/143448.
  • CB2 cannabinoid receptor
  • the compound of the formula I is administered in combination with histamine 1 agonists like those described for example in WO 2005/101979.
  • the compound of the formula I is administered in combination with bupropion as described in WO 2006/017504.
  • the compound of the formula I is administered in combination with opioid antagonists like those described for example in WO 2005/107806 or WO 2004/094429.
  • the compound of the formula I is administered in combination with neutral endopeptidase inhibitors like those described for example in WO 2002/02513, WO 2002/06492, WO 2002/040008, WO 2002/040022 or WO 2002/047670.
  • the compound of the formula I is administered in combination with NPY inhibitors (neuropeptide Y) like those described for example in WO 2002/047670.
  • NPY inhibitors neuropeptide Y
  • the compound of the formula I is administered in combination with sodium/hydrogen exchange inhibitors like those described for example in WO 2003/092694. In one embodiment of the invention, the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor like those described for example in WO 2005/090336.
  • the compound of the formula I is administered in combination with nicotine receptor agonists like those described for example in WO 2004/094429.
  • the compound of the formula I is administered in combination with NRIs (norepinephrine reuptake inhibitors) like those described for example in WO 2002/053140.
  • the compound of the formula I is administered in combination with MOA (E-beta-methoxyacrylate) such as, for example, segeline or like those described for example in WO 2002/053140.
  • MOA E-beta-methoxyacrylate
  • the compound of the formula I is administered in combination with antithrombotic active ingredients such as, for example, clopidrogel.
  • EL is released as secretory protein in high concentration into cell culture medium (conditioned medium) by recombinant cell lines (CHO, HEK293). This is employed as an enzyme solution after concentration.
  • the phospholipase-specific substrate 1 2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a- diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine (manufacturer Molecular Probes) is used to characterize the enzymatic activity of endothelial lipase and the effect of inhibitors. Hydrolysis of the A1 ester linkage of this phospholipid by the enzyme liberates a fatty acid labeled with the fluorescent dye Bodipy which can be detected after separation by thin-layer chromatography on an HPTLC plate (silica gel 60, Merck) or directly in the reaction vessel by measuring the fluorescence.
  • the substrate solution is prepared by dissolving 100 ⁇ g of 1 ,2-bis(4,4-difluoro-5,7- dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-s/i-glycero-3-phospho-choline (manufacturer Molecular Probes) in 100 ⁇ l of DMSO and taking up in 2.4 mg of tripalmitin (Sigma) in 393 ⁇ l of chloroform which comprises 20 mg/ml of DOP-choline (1 ,2-dioleoyl-sn-glycero-3-phosphocholine). 39.3 ⁇ l of this lipid mixture are transferred into a fresh reaction vessel, and the solvent is evaporated off.
  • the subsequent enzymic reaction takes place at 37°C for 90 minutes.
  • 20 ⁇ l of the substrate solution are incubated with 2 ⁇ l of inhibitor of appropriate concentration (dissolved in 10% DMSO, using 10% strength DMSO solution for control) and 2 ⁇ l of enzyme solution (conditioned medium).
  • 4 ⁇ l of the assay mixture are loaded onto an HPTLC plate (silica gel 60, Merck), and the liberated fluorescent dye is separated for detection with a mobile phase (diethyl etherpetroleum spirit:acetic acid [78:22:1]). After evaporation of the mobile phase, the plate is read in a fluorescence scanner. An increased liberation of the fluorescent dye in the uninhibited reaction is observed as a measure of the enzyme activity.
  • the enzymatic activity is reduced as a function of the inhibitor concentration used, and the inhibitor concentration at which a half-maximum enzymatic activity is observed is called IC 50 -
  • test models Suitability of the compounds of the invention as active pharmaceutical ingredient can be tested by means of various test models. Descriptions are given of such test models by way of example below. Solubility in aqueous systems
  • Solubility in aqueous systems can be determined by various methods. Suitable examples of solution precipitation methods ("kinetic solubility") and methods which investigate the dissolution of a solid sample until an equilibrium is set up (“thermodynamic solubility”), a) Kinetic solubility
  • a DMSO solution of the test compound (2.5 mM; 0.5 ⁇ l_) is pipetted into 200 ⁇ L of an aqueous test solution (e.g. phosphate-buffered saline, 1Ox, 1 M, Sigma, adjusted to 10 mM, pH 7.4) in a 96-well microtiter plate, and the turbidity is measured at the resulting theoretical concentration for the test compound of 6.25 ⁇ M using a nephelometer (e.g. Nephelostar Galaxy, BMG Labtech).
  • an aqueous test solution e.g. phosphate-buffered saline, 1Ox, 1 M, Sigma, adjusted to 10 mM, pH 7.4
  • a nephelometer e.g. Nephelostar Galaxy, BMG Labtech
  • the concentration of the test compound in the aqueous test solution is then raised to a theoretical 12.5 ⁇ M by adding further DMSO solution (2.5 mM; 0.5 ⁇ L), and the turbidity measurement is repeated. Further additions of DMSO solutions (1 ⁇ L, 2.5 mM; 0.5 ⁇ L, 10 mM; then 9x 1 ⁇ L, 10 mM resulting in theoretical concentrations of 25 ⁇ M, 50 ⁇ M, 100 ⁇ M, 150 ⁇ M, 200 ⁇ M, 250 ⁇ M, 300 ⁇ M, 350 ⁇ M, 400 ⁇ M, 450 ⁇ M and 500 ⁇ M) with turbidity measurement in between complete the measurement process.
  • the turbidity values from the nephelometer are plotted against the theoretical concentration of the test compound in the aqueous test solution. As soon as a significant turbidity is detected (e.g. 5 times above the control value of the aqueous test solution) at a theoretical concentration, the level of concentration below this is stated to be the solubility limit of the test compound in the test solution. Thus, the maximum possible measurement range emerges as values ⁇ 6.25 ⁇ M, 6.25 - 500 ⁇ M and >500 ⁇ M.
  • Preferred compounds of the invention show a kinetic solubility in phosphate buffer (pH 7.4) of at least 12.5 ⁇ M; more preferably of at least 50 ⁇ M and even more preferably of at least 250 ⁇ M.
  • the integrated UV absorption from HPLC UV measurement of serial dilutions of the test compound in DMSO shows a linear correlation with the concentration in a calibration line.
  • the test compound (500 ⁇ g) is shaken together with the aqueous test solution (250 ⁇ l_) in a closed vessel (capacity: 1.5 ml_) for 16 hours (Eppendorf thermoshaker, 1400 rpm, 25 0 C 1 covering to protect from light).
  • the sample is then centrifuged at maximum rotational speed, and the supernatant is finally filtered. A sample of the filtered supernatant is analyzed directly by HPLC UV measurement (see above).
  • a further sample is analyzed after dilution (1 part by volume of supernatant, 39 parts by volume of test solution). Evaluation: The concentration of the test compound in the undiluted supernatant is calculated from the resulting integrated UV absorptions of the supernatant samples on the basis of the constructed calibration lines and stated as solubility of the test compound in the respective aqueous test solution.
  • aqueous test solutions are deionized water or aqueous phosphate buffer with various pH values (e.g. pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0) which can be prepared from the commercial solution (phosphate buffered saline, 10x, Sigma) by dilution and adjustment with phosphoric acid or sodium hydroxide solution by standard methods.
  • pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0 phosphated saline, 10x, Sigma
  • Preferred compounds of the invention show a solubility in phosphate buffer (pH 7.4) of at least 12.5 ⁇ M; more preferably of at least 50 ⁇ M and even more preferably of at least 250 ⁇ M.
  • the metabolic stability is determined by incubating the test compound (5 ⁇ M) with microsomal liver fractions (1 mg/mL protein with 0.1 % w/v BSA; 1 mM NADPH, 0.5% DMSO) at 37°C. Analysis at an incubation time of 0 and 20 minutes takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Plant, N.; Drug Discovery Today 2004, 9(7), 328-336 and Lau, Y.Y. et al.; Pharmaceutical Res. 2002, 19(11), 1606-1610. Process for preparation
  • the R6 radicals may also be introduced subsequently by the abovementioned methods A, B or C, especially when R1 and R1 ' are different.
  • the compounds of the formula I obtained by above-described processes can be separated by known separation processes, for example chromatographic processes, in order to isolate, for example, monosubstituted from disubstituted imidazopyridin-2- ones.
  • the reactions may be performed within wide temperature ranges. In general, it has been found to be advantageous to work at from 0°C up to the boiling point of the solvent used.
  • the solvents used include, for example, methylene chloride, THF, DMF, toluene, ethyl acetate, n-heptane, dioxane, diethyl ether or pyridine.
  • imidazopyridin-2-one derivatives used are starting compounds Il are commercially available or can be prepared by literature processes (for example, G. P. Zecchini, I. Torrini and M. P. Paradisi, J. Het. Chem. (1985) 22, 313-318; G. P. Zecchini, I. Torrini and M. P. Paradisi, J. Het. Chem. (1985) 22, 1061-1064).
  • N-Hexyl-3-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxamide In 2.5 ml of DMF, N-hexyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxamide (65 mg, 0.248 mmol), iodomethane (70 mg, 0.5 mmol) and cesium carbonate (80 mg, 0.25 mmol) were stirred at RT for 5 h.
  • N-Hexyl-7-methyl-2-oxo-1 ,2-dihydroimidazo[4,5-b]pyridine-3-carboxamide Analogously to Example 1 , tert-butyl 7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine- 1-carboxylate (300 mg, 1.2 mmol), 1-isocyanatohexane (183.8 mg, 1.44 mmol) and 4- dimethylaminopyridine (14.7 mg, 0.12 mmol) were reacted in toluene. Yield: 8 mg (2%), M+H+: 277.16.
  • Example 7 tert-Butyl 3-hexylcarbamoyl-7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1- carboxylate
  • tert-butyl 7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine- 1-carboxylate (200 mg, 0.8 mmol) and 1-isocyanatohexane (113 mg, 0.88 mmol) were reacted in dioxane. Yield: 5 mg (2%), M+H+: 377.20.
  • N,N'-bishexyl-2-oxoimidazo[4,5-c]pyridine-1 ,3-dicarboxamide was isolated from the mixture in Example 6. Yield: 16 mg (1 %), M+H+: 390.28.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to imidazopyridin-2-one derivatives of the formula (I) with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments. The compounds are inhibitors of endothelial lipase.

Description

IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE
The present invention relates to imidazopyridin-2-one derivatives of the formula I, to their pharmaceutically usable salts and to their use as medicaments.
In addition to the imidazopyridin-2-one derivatives described in the present application, structurally similar compounds with pharmacological action have already been described in the prior art. For instance, US4144341 describes imidazopyridin-2-one derivatives for the treatment of fever and pain. WO02/30886 describes angiogenesis inhibitors which have an imidazopyridin-2-one base structure among other compounds.
Compounds with inhibitory action on endothelial lipase are described in the prior art, for example in WO2004/094394, WO2004/094393 or WO2004/093872.
It is an object of the present invention to provide alternative compounds which bring about inhibition of endothelial lipase.
The invention provides imidazopyridin-2-one derivatives of the formula I
Figure imgf000002_0001
where: X is the same or different and is =C(-R)- or =N-, where at least one X and at most two X are =N-; W is -(C=O)-, -(S=O)-, -(SO2)-;
R is the same or different and is hydrogen, halogen, (Ci-CβJ-alkyl, (C1-C3)- haloalkyl, (CrC3)-alkyloxy-(Ci-C3)-alkylene, aryl, heterocycle, hydroxyl, (Ci-C6)-alkyloxy, (CrC3)-haloalkyloxy, aryloxy, cyano, nitro, -S(O)p-(Cr C6)-alkyl, where p= 0, 1 or 2, aminosulfonyl, pentafluorosulfanyl, amino, (CrCeJ-alkylamino, di-(C2-Ci2)-alkylamino, (Ci-C6)-alkylcarbonyl, COOR3, CO-NR4R5 , O-CO-NR4R5, O-CO-(CrC6)-alkylene-CO-O-(Ci- CeJ-alkyl. O-CO-Cd-CeJ-alkylene-CO-OH. O-CO-Cd-CeJ-alkylene-CO- NR4R5;
R1 , R1 ' are the same or different and are each (C5-Ci6)-alkyl, (C5-Ci2)-cycloalkyl, (CrC^-alkylenearyl, (CrC-O-alkyleneheteroaryl, (Ci-C4)-alkylene-(C5- Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (d-C6)-alkyl, (C-I-CΘ)- alkyloxy, hydroxyl, (CrCβJ-alkylmercapto, amino, (Ci-C6)-alkylamino, di- (C2-Ci2)-alkylamino, mono-(Ci-C6)-alkylaminocarbonyl, di-(C2-Cβ)- alkylaminocarbonyl, (CrC6)-alkyloxycarbonyl, (CrC6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, pentafluorosulfanyl, (Cr C6)-alkylsulfonyl, aminosulfonyl;
R1 " is (Ci-Ciβ)-alkyl, (C5-C12)-cycloalkyl, (CrC4)-alkylenearyl, (Ci-C4)- alkyleneheteroaryl, (Ci-C4)-alkylene-(C5-Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, (C1-C6)- alkylmercapto, amino, (Ci-CβJ-alkylamino, di-(C2-C12)-alkylamino, mono- (Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (Ci-Cβ)- alkyloxycarbonyl, (CrC6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, (CrC6)-alkylsulfonyl, aminosulfonyl;
R2 is hydrogen;
R3 is the same or different and is hydrogen, (C-i-CδJ-alkyl, benzyl;
R4, R5 are the same or different and are each hydrogen, (Ci-C6)-alkyl, aryl, (C3-
C12)-cycloalkyl, (Ci-C4)-alkylenearyl, (Ci-C3)-alkylene-(C3-Ci2)-cycloalkyl; R6 is hydrogen, (Ci-C-ιo)-alkyl, (Ci-C4)-alkylenearyl, (C-,-C4)-alkylene- heterocycle, (Ci-C4)-alkylene-(C3-Ci2)-cycloalkyl, bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (CrCβJ-alkyloxy, hydroxy, (C-i-Cβ)- alkylmercapto, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono- (Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (CrCβ)- alkoxycarbonyl,
Figure imgf000004_0001
trifluoromethyl, trifluoromethyloxy, cyano, (Ci-CβJ-alkylsulfonyl, aminosulfonyl; or
-(C=O)-NRI ' R2; or
-(C=O)-O-RI ";
with the proviso that, when R1 is (C5-Ci6)-alkyl, R6 is not (Ci-C4)-alkylenearyl, (C1-C4)- alkylene-heterocycle, (Ci-C4)-alkylene-(C3-Ci2)-cycloalkyl or bicycle;
the tautomeric forms of the compounds and their physiologically compatible salts.
Preference is given to compounds of the formula I in which
W is -(C=O)-.
Preference is equally given to compounds of the formula I in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-.
Preference is also given to compounds of the formula I in which X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, (Ci-C6)-alkyl, hydroxyl, phenoxy, trifluoromethyl, COOR3, pentafluorosulfanyl, amino, (Ci-Cβ)- alkylamino, di-(C2-C8)-alkylamino, (CrC6)-alkylsulfonyl, aminosulfonyl, phenyl, (C5-C7)-heterocycle, (Ci-C6)-alkylcarbonyl, CO-NR4R5, O-CO- NR4R5, O-CO-(C1-C6)-alkylene-CO-O-(Ci-C6)-alkyl, 0-CO-(CrC6)- alkylene-CO-NR4R5 or unsubstituted or mono- or poly-F-substituted (d-
C3)-alkyloxy;
R1 , R1 ' are the same or different and are each (C6-Ci2)-alkyl, (Ci-C3)- alkylenearyl, (Ci-C3)-alkylene-heterocycle, (CrC3)-alkylene-(C5-Ci2)- cycloalkyl, (C8-Ci4)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (CrC3)-alkyloxy, hydroxyl, amino, (Ci-C6)-alkylamino, (CI-CΘ)- alkyloxycarbonyl, (Ci-CβJ-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R1 " is (Ci-Ci2)-alkyl, (Ci-C3)-alkylenearyl, (Ci-C3)-alkylene-heterocycle,
(Ci-C3)-alkylene-(C5-Ci2)-cycloalkyl, (C8-Ci4)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (C-i-C3)-alkyloxy, hydroxyl, amino, (Ci-C6)-alkylamino, (Ci-C6)-alkyloxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R2 is hydrogen;
R3 is hydrogen, (Ci-C6)-alkyl, benzyl; R4, R5 are the same or different and are each hydrogen, (Ci-CβJ-alkyI, (C3-Ci2)- cycloalkyl, phenyl, (Ci-C4)-alkylenephenyl, (Ci-C4)-alkylene-(C4-C12)- cycloalkyl;
R6 is hydrogen, (C-i-Cio)-alkyl, (Ci-C4)-alkylene-phenyl, (CrC4)-alkylene- heterocycle, (Ci-C4)-alkylene-(C3-Ci2)-cylcoalkyl, where phenyl, heterocycle, cycloalkyl may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, (C1-C6)- alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (Ci-C6)-alkylsulfonyl; or
-(C=O)-NR1 'R2 or -(C=O)-O-RI "; the tautomeric forms of the compounds and their physiologically compatible salts.
Preference is also given to the compounds of the formula I in which
X in positions 5 and 6 are identical or different and are each =C(-R)-, and in position 7 or 4 is =N-.
Further preferred compounds are those of the formula I in which
X in positions 4, 5 and 6 are identical or different and are each =C(-R)-, and in position 7 is =N-.
Particular preference is given to the compounds of the formula I in which X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, (CrC6)-alkyl, trifluoromethyl, hydroxyl, amino, (CrC6)-alkylcarbonyl, COOR3, (CrC6)- alkylsulfonyl, pentafluorosulfanyl, or unsubstituted or mono- or poly-F- substituted (C-i-C3)-alkyloxy;
R1 , RT are the same or different and are each (C6-CiO)-alkyl, -CH2-phenyl, (Ci- C2)-alkyleneheteroaryl or bicycle of the formula Ic
Ic
Figure imgf000007_0001
where q = 1 or 2, where phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, amino, (C-i-C6)-alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R1 " is (C-ι-Cio)-alkyl, -CH2-phenyl, (CrC2)-alkyleneheteroaryl or bicycle of the formula Ic
Ic
Figure imgf000007_0002
where q = 1 or 2, where phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (CrC6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, amino, (C-i-CβJ-alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy; R2 is hydrogen;
R3 is hydrogen, (CrC6)-alkyl;
R6 is hydrogen, (Ci-Ca)-alkyl, (CrC^-alkylene-phenyl, (CrC4)-alkylene- heteroaryl, where phenyl or heteroaryl may be mono- or polysubstituted by halogen, (d-C6)-alkyl, (d-C^-alkyloxy, hydroxyl, (CrC6)- alkoxycarbonyl, (CrCβJ-alkylcarbonyl, trifluoromethyl; or -(C=O)-NRI 'R2 or
-(C=O)-O-RI "; the tautomeric forms of the compounds and their physiologically compatible salts.
Very particular preference is given to the compounds of the formula I in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, hydroxyl, (Ci-Cβ)- alkyloxy, trifluoromethyl, (Ci-CβJ-alkylcarbonyl or (Ci-CβJ-alkyl;
R1 , R1 ' are the same or different and are each (C6-Cio)-alkyl, -CH2-phenyl or bicycle of the formula Ic Ic
Figure imgf000009_0001
where q = 1 or 2, where phenyl or bicycle may be mono- to disubstituted by halogen, (Ci-C6)-alkyl, (CVC^-alkyloxy, (Ci-C6)-alkylcarbonyl, trifluoromethyl;
R1 " is (CrCio)-alkyl, -CH2-phenyl or bicycle of the formula Ic
Ic
Figure imgf000009_0002
where q = 1 or 2, where phenyl or bicycle may be mono- to disubstituted by halogen, (Ci-C6)-alkyl, (C-i-C3)-alkyloxy, (CrC6)-alkylcarbonyl, trifluoromethyl;
R2 is hydrogen;
R6 is hydrogen, (Ci-C4)-alkyl, CH2-phenyl, where phenyl may be mono- or polysubstituted by halogen, (C-i-C6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, (Cr C6)-alkylcarbonyl, trifluoromethyl; or
-(C=O)-NRI 'R2 or
-(C=O)-O-RI "; the tautomeric forms of the compounds and their physiologically compatible salts.
A particular preference is given to the compounds of the formula I in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-; 10
C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono-(CrC6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (CrC6)-alkoxycarbonyl, (CI-CΘ)- alkylcarbonyl, trifluoromethyl, trifluoromethyloxy, cyano, (CrCβ)- alkylsulfonyl, aminosulfonyl; with the proviso that, when R1 is (C5-C-ι6)-alkyl, R6 is not (Ci-C4)-alkylenearyl.
In a further preferred embodiment of the compounds of the formula I, R6 is -(C=O)-NRI 'R2.
In another preferred embodiment of the compounds of the formula I, R6 is -(C=O)-O-RI ".
The invention relates to compounds of the formula I in the form of their salts, racemates, racemic mixtures and pure enantiomers, and also to their diastereomers and mixtures thereof.
The alkyl or alkylene radicals in the substituents R, R1 , R1 ', R1 ", R2, R3, R4, R5 and R6 may be either straight-chain or branched. Halogen is fluorine, chlorine, bromine or iodine, particularly fluorine or chlorine.
Haloalkyl is an alkyl substituted singly, multiply or fully by halogen. Preferred halogens are fluorine and chlorine.
A cycloalkyl radical is understood to mean a ring system which comprises one or more rings and is saturated or partially unsaturated (with one or two double bonds), which is composed exclusively of carbon atoms, for example cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl or adamantyl. The cycloalkyl radicals may be mono- or polysubstituted by suitable groups, for example F, Cl, Br, I1 CF3, NO2, N3, CN, COOH, COO(Ci-C6)alkyl, CONH2, CONH(C1- R is the same or different and is hydrogen, methyl;
R1 , R1 ' are the same or different and are each (C6-Cio)-alkyl, -CH2-phenyl or bicycle of the formula Id
Id
Figure imgf000011_0001
where q = 1 , where phenyl or bicycle may be substituted by methyl;
R2 is hydrogen;
R6 is hydrogen, methyl, or
-(C=O)-NRI 'R2;
the tautomeric forms of the compound and its physiologically compatible salts.
In a further preferred embodiment of the compounds of the formula I, W is -(SO2)-.
In a further preferred embodiment of the compounds of the formula I,
R6 is hydrogen, (Ci-C4)-alkyl, (Ci-C4)-alkylenearyl, preferably hydrogen or (Ci-C4)-alkyl, more preferably hydrogen, methyl, ethyl, n-propyl or n- butyl, most preferably hydrogen or methyl; where aryl may be mono- or polysubstituted preferably by halogen, (C1- C6)-alkyl, (CrCβJ-alkyloxy, hydroxyl, (Ci-C6)-alkylmercapto, amino, (d- C6)alkyl, CON[(CrC6)alkyl]2, cycloalkyl, (CrCi0)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(CrC6)-alkyl, O-CO-(Ci-C6)-alkyl, O-CO-(Ci-C6)-aryl, O-CO-(CrC6)-heterocycle; PO3H2, SO3H, SO2-NH2, SO2NH(CrC6)-alkyl, SO2N[(Ci-C6)-alkyl]2 , S-(Ci-C6)-alkyl, S- (CH2)n-aryl, S-(CH2)n-heterocycle, SO-(CrC6)-alkyl, SO-(CH2)n-aryl, SO-(CH2)n- heterocycle, SO2-(CrC6)-alkyl, SO2-(CH2)n-aryl, SO2-(CH2)n-heterocycle , SO2- NH(CH2)n-aryl, SO2-N H(CH2)n-heterocycle, Sθ2-N((C1-C6)-alkyl)(CH2)n-aryll SO2- N((Ci-C6)-alkyl)(CH2)n-heterocycle, SO2-N((CH2)n-aryl)2, SO2-N((CH2)n-heterocycle)2 where n may be 0 - 6 and the aryl radical or heterocyclic radical may be up to disubstituted by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(CrC6)-alkyl, (Ci-C6)-alkyl, NH2;
C(NH)(NH2), NH2, NH-(CrC6)-alkyl, N((CrC6)-alkyl)2, NH(CrC7)-acyl, NH-CO-(C1-C6)- alkyl, NH-COO-(Ci-C6)-alkyl, NH-CO-aryl, NH-CO-heterocycle, NH-COO-aryl, NH- COO-heterocycle, NH-CO-NH-(CrC6)-alkyl, NH-CO-NH-aryl, NH-CO-NH-heterocycle, N(Ci-C6)-alkyl -CO-(Ci-C6)-alkyl, N(CrC6)-alkyl -COO-(CrC6)-alkyl, N(CrC6)-alkyl - CO-aryl, N(CrC6)-alkyl -CO-heterocycle, Ntd-CeJ-alkyl -COO-aryl, N(CrC6)-alkyl - COO-heterocycle, N(CrC6)-alkyl -CO-NH-(CrC6)-alkyl, N(Ci-C6)-alkyl -CO-NH-aryl, N(Ci-C6)-alkyl -CO-NH-heterocycle, N((C1-C6)-alkyl)-CO-N-((C1-C6)-alkyl)2, N((CrC6)- alkyl)-CO-N((Ci-C6)-alkyl)-aryl) N((C1-C6)-alkyl)-CO-N((C1-C6)-alkyl)-heterocycle, N((CrC6)-alkyl)-CO-N-(aryl)2, N((CrC6)-alkyl)-CO-N-(heterocycle)2, N(aryl)-CO-(Ci- C6)-alkyl, N(heterocycle)-CO-(Ci-C6)-alkyl, N(aryl)-COO-(CrC6)-alkyl, N(heterocycle)- COO-(Ci-C6)-alkyl, N(aryl)-CO-aryl, N(heterocycle)-CO-aryl, N(aryl)-COO-aryl, N(heterocycle)-COO-aryl, N(aryl)-CO-NH-(C1-C6)-alkyl, N(heterocycle)-CO-NH-(Cr C6)-alkyl, N(aryl)-CO-NH-aryl, N(heterocycle)-CO-NH-aryl, N(aryl)-CO-N-((Ci-C6)- alkyl)2, N(heterocycle)-CO-N-((C1-C6)-alkyl)2, N(aryl)-CO-N((C1-C6)-alkyl)-aryl, N(heterocycle)-CO-N((C1-C6)-alkyl)-aryl, N(aryl)-CO-N-(aryl)2, N(heterocycle)-CO-N- (aryl)2l aryl, O-(CH2)n-aryl, O-(CH2)n-heterocycle, where n may be O - 6, where the aryl radical or heterocyclic radical may be mono- to trisubstituted by F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(CrC6)-alkyl, (CrC6)-alkyl, NH2, NH(C1-C6)-alkyl, N((CrC6)-alkyl)2, SO2-CH3, COOH, COO-(d-C6)-alkyl, CONH2. Bicycle is a partly unsaturated bicyclic ring system which has from 8 to 14 ring members and has exclusively carbon atoms as ring members. Ring systems which contain a fused benzene ring are included in this definition. Mention is made by way of example of the tetrahydronaphthyl, alpha- or beta-tetralonyl, indanyl or indan-1-onyl radical. Preferred bicycle radicals are tetrahydronaphthyl and indanyl.
The bicycle radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl1 Br1 I, CF3, NO2, N3, CN, COOH, COO(CrC6)alkyl, CONH2, CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, cycloalkyl, (CrC10)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(C1- C6)-alkyl, O-CO-(Ci-C6)-alkyl, O-CO-(Ci-C6)-aryl, O-CO-(CrC6)-heterocycle; PO3H2, SO3H, SO2-NH2, SO2NH(Ci-C6)-alkyl, SO2N[(CrC6)-alkyl]2 , S-Cd-CeJ-alkyl, S- (CH2)n-aryl, S-(CH2)n-heterocycle, SO-(CrC6)-alkyl, SO-(CH2)n-aryl, SO-(CH2)n- heterocycle, SO2-(CrC6)-alkyl, SO2-(CH2)n-aryl, SO2-(C H2)n-heterocycle , SO2- NH(CH2)n-aryl, SO2-NH(CH2)n-heterocycle,
Figure imgf000013_0001
SO2-N((Cr C6)-alkyl)(CH2)n-heterocycle, SO2-N((CH2)n-aryl)2, SO2-N((CH2)n-heterocycle)2 where n may be O - 6 and the aryl radical or heterocyclic radical may be up to disubstituted by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(CrC6)-alkyl, (Ci-C6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(Ci-C6)-alkyl, N((C1-C6)-alkyl)2, NH(Ci-C7)-Acyl, NH-CO-(C1-C6)- alkyl, NH-COO-(CrC6)-alkyl, NH-CO-aryl, NH-CO-heterocycle, NH-COO-aryl, NH- COO-heterocycle, NH-CO-NH-(CrC6)-alkyl, NH-CO-NH-aryl, NH-CO-NH-heterocycle, N(CrC6)-alkyl -CO^d-Ce^alkyl, N(CrC6)-alkyl -COO^d-CeJ-alkyl, N(CrC6)-alkyl - CO-aryl, N(CrC6)-alkyl -CO-heterocycle, N(CrC6)-alkyl -COO-aryl, Nfd-CeJ-alkyl - COO-heterocycle, N(CrC6)-alkyl -CO-NH-^rCeJ-alkyl, N(C1-C6)-alkyl -CO-NH-aryl, N(C1-C6)-alkyl -CO-NH-heterocycle, N((C1-C6)-alkyl)-CO-N-((C1-C6)-alkyl)2, N((CrC6)- alkyl)-CO-N((CrC6)-alkyl)-aryl, N((C1-C6)-alkyl)-CO-N((C1-C6)-alkyl)-heterocycle, N((CrC6)-alkyl)-CO-N-(aryl)2, NKCrCeJ-alkyO-CO-N^heterocycleh, N(aryl)-CO-(Cr C6)-alkyl, N(heterocycle)-CO-(CrC6)-alkyl, N(aryl)-COO-(C1-C6)-alkyl, N(heterocycle)- COO^CrCeJ-alkyl, N(aryl)-CO-aryl, N(heterocycle)-CO-aryl, N(aryl)-COO-aryl, N(heterocycle)-COO-aryl, N(aryl)-CO-NH-(CrC6)-alkyl, N(heterocycle)-CO-NH-(Cr C6)-alkyl, N(aryl)-CO-NH-aryl, N(heterocycle)-CO-NH-aryl, N(aryl)-CO-N-((CrC6)- alkyl)2, N(heterocycle)-CO-N-((Ci-C6)-alkyl)2, N(aryl)-CO-N((C1-C6)-alkyl)-aryl,
N(heterocycle)-CO-N((CrC6)-alkyl)-aryl, N(aryl)-CO-N-(aryl)2, N(heterocycle)-CO-N- (aryl)2l aryl, O-(CH2)n-aryl, O-(CH2)n-heterocycle, where n may be 0 - 6, where the aryl radical or heterocyclic radical may be mono- to trisubstituted by F, Cl, Br, I1 OH, CF3, NO2, CN, OCF3, O-(Ci-C6)-alkyl, (CrC6)-alkyl, NH2, NH(CrC6)-alkyl, N((Ci-C6)-alkyl)2, SO2-CH3, COOH, COO-(CrC6)-alkyl, CONH2.
An aryl radical is understood to mean a phenyl or naphthyl radical. The aryl radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br, I, CF3, NO2, CN, COOH, COO(d-C6)alkyl, CONH2, CONH(CrC6)alkyl, CON[(d-C6)alkyl]2, , (C3-Ci0)-cycloalkyl, (d-C10)-alkyl, (C2-C6)-alkenyl, (C2-C6)- alkynyl, O-(Ci-C6)-alkyl, O-CO-(Ci-C6)-alkyl, O-CO-(CrC6)-aryl,
PO3H2, SO3H, SO2-NH2, SO2NH(d-C6)-alkyl, SO2N[(CrC6)-alkyl]2 , S-(d-C6)-alkyl, S- (CH2)n-aryl, S-(CH2)n-heterocycle, SO-(d-C6)-alkyl, SO-(CH2)n-aryl, SO-(CH2)n- heterocycle, SO2-(CrC6)-alkyl, SO2-(CH2)n-aryl, SO2-(CH2)n-heterocycle , SO2- NH(CH2)n-aryl, SO2-NH(CH2)n-heterocycle, SO2-N((d-C6)-alkyl)(CH2)n-aryl, SO2- N((Ci-C6)-alkyl)(CH2)n-heterocycle, SO2-N((CH2)n-aryl)2, SO2-N((CH2)n-(heterocycle)2 where n may be O - 6 and the aryl radical or heterocyclic radical may be up to disubstituted by F, Cl, Br1 OH, CF3, NO2, CN, OCF3, O-(d-C6)-alkyl, (Ci-C6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(d-C6)-alkyl, N((d-C6)-alkyl)2, NH(d-C7)-Acyl, NH-CO-(C1-C6)- alkyl, NH-COO-(d-C6)-alkyl, NH-CO-aryl, NH-CO-heterocycle, NH-COO-aryl, NH- COO-heterocycle, NH-CO-NH-(d-C6)-alkyl, NH-CO-NH-aryl, NH-CO-NH-heterocycle, N(Ci-C6)-alkyl -CO-(d-C6)-alkyl, N(Ci-C6)-alkyl -COO-(d-C6)-alkyl, N(d-C6)-alkyl - CO-aryl, N(d-C6)-alkyl -CO-heterocycle, N(d-C6)-alkyl -COO-aryl, N(CrC6)-alkyl - COO-heterocycle, N(d-C6)-alkyl -CO-NH-(d-C6)-alkyl, N(d-C6)-alkyl -CO-NH-aryl, N(Ci-C6)-alkyl -CO-NH-heterocycle, N((CrC6)-alkyl)-CO-N-((Ci-C6)-alkyl)2, N((d-C6)- alkyl)-CO-N((Ci-C6)-alkyl)-aryl, N((d-C6)-alkyl)-CO-N((Ci-C6)-alkyl)-heterocycle, N((C1-C6)-alkyl)-CO-N-(aryl)2, N((Ci-C6)-alkyl)-CO-N-(heterocycle)2, N(aryl)-CO-(Cr C6)-alkyl, N(heterocycle)-CO-(d-C6)-alkyl, N(aryl)-COO-(d-C6)-alkyl, N(heterocycle)- COO-(Ci-C6)-alkyl, N(aryl)-CO-aryl, N(heterocycle)-CO-aryl, N(aryl)-COO-aryl, N(heterocycle)-COO-aryl, N(aryl)-CO-NH-(d-C6)-alkyl, N(heterocycle)-CO-N H-(C1- C6)-alkyl, N(aryl)-CO-NH-aryl, N(heterocycle)-CO-NH-aryl, N(aryl)-CO-N-((CrC6)- alkyl)2, N(heterocycle)-CO-N-((Ci-C6)-alkyl)2, N(aryl)-CO-N((Ci-C6)-alkyl)-aryl, N(heterocycle)-CO-N((CrC6)-alkyl)-aryl, N(aryl)-CO-N-(aryl)2, N(heterocycle)-CO-N- (aryl>2, aryl, O-(CH2)n-aryl, O-(CH2)n-heterocycle, where n may be 0 - 6, where the aryl radical or heterocyclic radical may be mono- to trisubstituted by F1 Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-(Ci-C6)-alkyl, (d-C6)-alkyl, NH2, NH(CrC6)-alkyl, N((Ci-C6)-alkyl)2, SO2-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2.
Heterocycle is a mono- or bicyclic ring system having from 5 to 12 ring members, in which at least one atom in the ring system is a heteroatom selected from the group consisting of N, O and S. This definition also includes ring systems in which the heterocycle is fused to a benzene ring. (C5-C7)-Heterocycle is a monocyclic ring system; (C8-Ci2)-heterocycle is a bicyclic ring system.
Suitable "heterocyclic rings" or "heterocyclic radicals" are azocinyl, benzimidazolyl, benzofuryl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH- carbazolyl, carbolinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1 ,5,2- dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuryl, furyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5- oxadiazolyl, 1 ,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1 ,2,5-thiadiazinyl, thiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4-thiadiazolyl, thienyl, triazolyl, tetrazolyl and xanthenyl.
Pyridyl is any of 2-, 3- or 4-pyridyl. Thienyl is either 2- or 3-thienyl. Furyl is either 2- or 3-furyl.
Also included are the corresponding N-oxides of these compounds, for example 1-oxy- 2-, -3- or -4-pyridyl.
The heterocyclic rings or heterocyclic radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br1 I1 CF3, NO2, N3, CN, COOH1 COO(Ci-C6)alkyl, CONH2, CONH(Ci-C6)alkyl, CON[(Ci-C6)alkyl]2, (d-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)- alkynyl, O-(Ci-C6)-alkyl, where one, more than one or all hydrogen(s) in the alkyl radicals may be replaced by fluorine; PO3H2, SO3H, SO2-NH2, SO2NH(CrC6)-alkyl, SO2N[(CrC6)-alkyl]2 , S-(CrC6)-alkyl, S- (CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, SO2-(Ci-C6)-alkyl, SO2-(CH2)n- phenyl, where n may be O - 6 and the phenyl radical may be up to disubstituted by F, Cl, Br1 OH, CF3, NO2, CN, OCF3, O-(Ci-C6)-alkyl, (C1-C6)-alkyl, NH2; C(NH)(NH2), NH2, NH-(Ci-C6)-alkyl, N((CrC6)-alkyl)2, NH(CrC7)-acyl, phenyl, O- (CH2)n-phenyl where n may be O - 6, where the phenyl ring may be mono- to trisubstituted by F1 Cl1 Br1 I1 OH1 CF3, NO2, CN1 OCF3, O-(CrC6)-alkyl, (Ci-C6)-alkyl, NH2, NH(CrC6)-alkyl, N((Ci-Cβ)-alkyl)2, SO2-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2.
Heteroaryl is a mono- or bicyclic aromatic ring system having from 5 to 12 ring members, in which at least one atom in the ring system is a heteroatom selected from the group consisting of N1 O and S. This definition also includes ring systems in which the heteroaryl is fused to a benzene ring. Suitable "heteroaryl rings" or "heteroaryl radicals" are, for example, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, furyl, furazanyl, imidazolyl, 1 H-indazolyl, indolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5- oxadiazolyl, 1 ,3,4-oxadiazolyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, thiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4-thiadiazolyl, thiophenyl. Preferred heteroaryl radicals are benzothiophenyl and thiophenyl. The heteroaryl rings or heteroaryl radicals may be mono- or polysubstituted by suitable groups, for example: F, Cl, Br, I1 CF3, NO2, N3, CN, COOH, COO(CrC6)alkyl, CONH2, CONH(Ci-C6)alkyl, CON[(CrC6)alkyl]2, (Ci-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(Ci-C6)-alkyl, where one, more than one or all hydrogen(s) in the alkyl radicals may be replaced by fluorine; PO3H2, SO3H, SO2-NH2, SO2NH(CrC6)-alkyl, SO2N[(CrC6)-alkyl]2 , S-(Ci-C6)-alkyl, S- (CH2)n-phenyl, SO-(CrC6)-alkyl, SO-(CH2)n-phenyl, SO2-(C1-C6)-alkyl, SO2-(CH2)n- phenyl where n may be O - 6 and the phenyl radical may be up to disubstituted by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-(Ci-C6)-alkyl, (d-CeJ-alkyl, NH2; C(NH)(NH2), NH2, NH-(CrC6)-alkyl, N((CrC6)-alkyl)2l NH(CrC7)-acyl, phenyl, O- (CH2)n-phenyl, where n may be O - 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O^d-CeJ-alkyl, (CrC6)-alkyl, NH2, NH(CrC6)-alkyl, N((CrC6)-alkyl)2, SO2-CH3, COOH, COO-(C1-C6)-alkyl, CONH2.
Owing to their higher water solubility, pharmaceutically acceptable salts are particularly suitable for medical applications compared to the starting or base compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the inventive compounds are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and organic acids, for example acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid and tartaric acid. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts) and salts of trometamol (2-amino-2- hydroxymethyl-1 ,3-propanediol), diethanolamine, lysine or ethylenediamine.
Salts with a pharmaceutically unacceptable anion, for example trifluoroacetate, are likewise included in the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for the use in non-therapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used here refers to any physiologically compatible derivative of an inventive compound of the formula I1 for example an ester which, on administration to a mammal, for example the human, is capable (directly or indirectly) of forming a compound of the formula I or an active metabolite thereof.
The physiologically functional derivatives also include prodrugs of the inventive compounds, as described, for example, in H. Okada et al., Chem. Pharm. Bull., 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to give an inventive compound. These prodrugs may themselves be active or not.
The inventive compounds may also be present in various polymorphic forms, for example as amorphous and crystalline polymorphic forms. All polymorphic forms of the inventive compounds are included within the scope of the invention and are a further aspect of the invention.
Hereinafter, all references to "compound(s) of the formula I" relate to compound(s) of the formula I as described above, and also their salts, solvates and physiologically functional derivatives as described herein. Use
The compounds of the formula I in which
X is the same or different and is =C(-R)- or =N-, where at least one X and at most two X are =N-;
W is -(C=O)-, -(S=O)-, -(SO2)-;
R is the same or different and is hydrogen, halogen, (d-CβJ-alkyl, (C1-C3)- haloalkyl, (Ci-C3)-alkyloxy-(Ci-C3)-alkylene, aryl, heterocycle, hydroxyl, (C-i-C6)-alkyloxy, (Ci-C3)-haloalkyloxy, aryloxy, cyano, nitro, -S(O)p-(Cr C6)-alkyl, where p = O, 1 or 2, aminosulfonyl, pentafluorosulfanyl, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, (CrC6)-alkylcarbonyl, COOR3, CO-NR4R5 , O-CO-NR4R5, O-CO-(Ci-C6)-alkylene-CO-O-(Ci-
C6)-alkyl, O-CO-(Ci-C6)-alkylene-CO-OH, O-CO-(Ci-C6)-alkylene-CO- NR4R5;
R1 , RT are the same or different and are each (C5-Ci6)-alkyl, (C5-Ci2)-cycloalkyl, (CrC4)-alkylenearyl, (Ci-C4)-alkyleneheteroaryl, (Ci-C4)-alkylene-(Cs-
Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (C-i-C6)-alkyl, (Ci-Cβ)- alkyloxy, hydroxyl, (Ci-C6)-alkylmercapto, amino, (Ci-C6)-alkylamino, di- (C2-Ci2)-alkylamino, mono-(Ci-C6)-alkylaminocarbonyl, di-(C2-Cβ)- alkylaminocarbonyl,
Figure imgf000019_0001
(Ci-C6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, pentafluorosulfanyl, (Cr C6)-alkylsulfonyl, aminosulfonyl;
R1 " is (Ci-Ci6)-alkyl, (C5-C12)-cycloalkyl, (Ci-C4)-alkylenearyl, (C1-C4)- alkyleneheteroaryl, (Ci-C4)-alkylene-(C5-Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (CrC6)-alkyloxy, hydroxyl, (CrC6)- alkylmercapto, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono- (Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (CrC6)- alkyloxycarbonyl, (CrC6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, (CrC6)-alkylsulfonyl, aminosulfonyl;
R2 is hydrogen;
R3 is the same or different and is hydrogen, (Ci-C6)-alkyl, benzyl;
R4, R5 are the same or different and are each hydrogen, (CrC6)-alkyl, aryl, (C3-
Ci2)-cycloalkyl, (CrC4)-alkylenearyl, (C1-C3)-alkylene-(C3-C12)-cycloalkyl;
R6 is hydrogen, (Ci-C-ιO)-alkyl, (CrC4)-alkylenearyl, (CrC4)-alkylene- heterocycle, (Ci-C4)-alkylene-(C3-C12)-cycloalkyl, (C8-Ci4)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (CrC6)-alkyloxy, hydroxyl, (C1-C6)- alkylmercapto, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono-
(Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (Ci-C6)- alkoxycarbonyl, (CrC6)-alkylcarbonyl, trifluoromethyl, trifluoromethyloxy, cyano, (Ci-C6)-alkylsulfonyl, aminosulfonyl; or
-(C=O)-NRI R2; or -(C=O)-NH2; or
-(C=O)-O-RI ";
and the tautomeric forms of the compounds and also their physiologically compatible salts have a surprising inhibitory effect on endothelial lipase (EL). HDL, which has antiatherosclerotic action, is the preferred substrate for EL. A lowering of the HDL level leads to the progression of atherosclerosis and its sequelae such as coronary heart disease and additionally promotes the development of metabolic syndrome and its sequela of diabetes. An inhibition of the EL should thus lead generally to the prevention of atherosclerotic disorders and indirectly reduce the probability of illness in persons with an increased risk of diabetes.
It has also been found that the inhibitory effect of the inventive compounds of the formula I is selective compared to other lipases.
The compounds of the formula I are notable for exhibiting an improved solubility compared with compounds of similar structure in aqeous media with at least the same time high activity. Preferred compounds of the invention further exhibit an improved metabolic stability compared with compounds of the prior art.
Furthermore the compounds of the invention show advantages in terms of serum stability.
Such compounds are particularly suitable for the treatment and/or prevention of
1. Dyslipidemias and general impairments of lipid metabolism and their sequelae, for example atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following factors:
- high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations,
- low HDL cholesterol concentration
- low ApoA lipoprotein concentrations - high LDL cholesterol concentrations
- small dense LDL cholesterol particles
- high ApoB lipoprotein concentrations 2. Various other conditions which may be associated with the metabolic syndrome, such as:
- obesity (excess weight), including central obesity
- thromboses, hypercoagulable and prothrombotic stages (arterial and venous) - high blood pressure
- heart failure, for example (but not restricted thereto) following myocardial infarction, hypertensive heart disease or cardiomyopathy
- diabetes mellitus, in particular type 2 diabetes, including the prevention of the sequelae associated therewith (hyperglycemia, glucose intolerance, loss of pancreatic β cells, macro- and microvascular disorders
3. Other disorders or conditions in which inflammatory reactions or cell differentiation, for example, are involved are:
- atherosclerosis, for example (but not restricted thereto) coronary sclerosis, including angina pectoris or myocardial infarction, stroke
- vascular restenosis or reocclusion
- chronic inflammatory bowel diseases, for example Crohn's disease and ulcerative colitis
- pancreatitis - other inflammatory states
- retinopathy
- adipose cell tumors
- adipose cell carcinomas, for example liposarcomas
- solid tumors and neoplasms, for example (but not restricted thereto) carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidney and the urinary tract, of the genital tract, prostate carcinomas, etc.
- acute and chronic myeloproliferative disorders and lymphomas
- angiogenesis - neurodegenerative disorders
- Alzheimer's disease - multiple sclerosis
- Parkinson's disease
- erythemato-squamous dermatoses, for example psoriasis
- acne vulgaris - other skin disorders and dermatological conditions which are modulated by
PPAR
- eczemas and neurodermatitis
- dermatitis for example seborrheic dermatitis or photodermatitis
- keratitis and keratoses, for example seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or keratosis follicularis
- keloids and keloid prophylaxis
- warts, including condylomata or condylomata acuminata
- human papilloma viral (HPV) infections, for example venereal papillomata, viral warts, for example molluscum contagiosum, leukoplakia - papular dermatoses, for example lichen planus
- skin cancer, for example basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas
- localized benign epidermal tumors, for example keratoderma, epidermal naevi
- chilblains - high blood pressure
- syndrome X
- polycystic ovary syndrome (PCOS)
- asthma
- osteoarthritis - lupus erythematosus (LE) or inflammatory rheumatic disorders, for example rheumatoid arthritis
- vasculitis
- wasting (cachexia)
- gout - ischemia/reperfusion syndrome
- acute respiratory distress syndrome (ARDS) ("shock lung"). Formulation
The amount of an inventive compound which is required in order to achieve the desired biological effect is dependent upon a series of factors, for example the specific compound selected, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3- 10 mg/kg/day. An intravenous dose may, for example, be in the range from 0.3 mg to 1.0 mg/kg and may suitably be administered as an infusion of from 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for these purposes may, for example, contain from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Ampoules for injections may therefore contain, for example, from 1 mg to 100 mg, and single dose formulations which can be administered orally, for example tablets or capsules, may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. The compounds of the formula I may be used for therapy of the abovementioned conditions as the compounds themselves, although they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier of course has to be acceptable, in the sense that it is compatible with the other constituents of the composition and is not damaging to the health of the patient. The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05 to 95% by weight of the active ingredient. Further pharmaceutically active substances may likewise be present, including further inventive compounds. The inventive pharmaceutical compositions may be produced by one of the known pharmaceutical methods which consist essentially in mixing the constituents with pharmacologically acceptable carriers and/or excipients.
Inventive pharmaceutical compositions are those which are suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the type of the compound of formula I used in each case. Coated formulations and coated slow-release formulations are also encompassed by the scope of the invention. Preference is given to acid- and gastric fluid-resistant formulations. Suitable gastric fluid-resistant coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
Suitable pharmaceutical preparations for oral administration may be in the form of separate units, for example capsules, cachets, lozenges or tablets, each of which contains a certain amount of the compound of the formula I; as powder or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional constituents) are brought into contact. In general, the compositions are prepared by uniform and homogeneous mixing of the active ingredient with a liquid carrier and/or finely divided solid carrier, after which the product is shaped if necessary. For example, a tablet can thus be produced by compressing or shaping a powder or granules of the compound, optionally with one or more additional constituents. Compressed tablets can be prepared by tableting the compound in free-flowing form, for example a powder or granules, optionally mixed with a binder, lubricant, inert diluent and/or one (or more) surfactants/dispersants in a suitable machine. Shaped tablets can be prepared by shaping the pulverulent compound moistened with an inert liquid diluent in a suitable machine.
Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound of formula I with a flavoring, customarily sucrose, and gum arabic or tragacanth, and pastilles which include the compound in an inert base, such as gelatin and glycerol or sucrose and gum arabic. Suitable pharmaceutical compositions for parenteral administration include preferably sterile aqueous preparations of a compound of the formula I which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations can preferably be produced by mixing the compound with water and making the solution obtained sterile and isotonic with the blood. Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active compound.
Suitable pharmaceutical compositions for rectal administration are preferably in the form of single dose suppositories. These can be prepared by mixing a compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
Suitable pharmaceutical compositions for topical application on the skin are preferably in the form of an ointment, cream, lotion, paste, spray, aerosol or oil. Useful carriers include petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, preferably from 0.5 to 2%.
Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal applications may be in the form of single plasters which are suitable for long-term close contact with the epidermis of the patient. Such plasters suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is from approx. 1 % to 35%, preferably from approx. 3% to 15%. A particular means of releasing the active ingredient may be by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986). The compounds of the formula I are notable for favorable effects on disorders of lipid metabolism. They positively influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of dyslipidemias and metabolic syndrome and their diverse sequelae such as atherosclerosis, coronary heart disease, heart failure, obesity and diabetes.
Combinations with other medicaments
The compounds of the invention can be administered alone or in combination with one or more further pharmacologically active ingredients. In particular, the compounds of the invention can be administered with active ingredients which have a similar pharmacological effect to themselves. For example, they can be administered in combination with active ingredients which have favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are
1. medicaments which lower blood glucose, antidiabetics,
2. active ingredients for the treatment of dyslipidemias,
3. antiatherosclerotic medicaments, 4. antiobesity agents,
5. antiinflammatory active ingredients
6. active ingredients for the treatment of malignant tumors
7. antithrombotic active ingredients
8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and
10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes
11. active ingredients for the treatment of neurodegenerative diseases 12. active ingredients for the treatment of diseases of the central nervous system 13. active ingredients for the treatment of dependence on drugs, nicotine and alcohol 14. analgesics
They can be combined with the compounds of the invention of the formula I in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
Further active ingredients particularly suitable for the combination products are: All antidiabetics which are mentioned in the Rote Liste 2006, chapter 12; all weight- reducing agents/appetite suppressants which are mentioned in the Rote Liste 2006, chapter 1 ; all lipid-lowering agents which are mentioned in the Rote Liste 2006, chapter 58. They can be combined with the compound of the invention of the formula I in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients mentioned hereinafter are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
Antidiabetics include insulin and insulin derivatives such as, for example, Lantus® (see www.lantus.com) or HMR 1964 or those described in WO 2005/005477 (Novo Nordisk), fast-acting insulins (see US 6,221 ,633), inhalable insulins such as, for example, Exubera ® or oral insulins such as, for example, IN-105 (Nobex) or Oral-lyn™ (Generex Biotechnology), GLP-1 -derivatives such as, for example, exenatide, liraglutide or those which have been disclosed in WO 98/08871 or WO 2005/027978 of Novo Nordisk A/S, in WO 01/04156 of Zealand or in WO 00/34331 of Beaufour-lpsen, Pramlintide Acetate (Symlin; Amylin Pharmaceuticals), and orally effective hypoglycemic active ingredients. The active ingredients include preferably sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, inhibitors of glycogen phosphorylase, glucagon antagonists, glucokinase activators, inhibitors of fructose-1 ,6-bisphosphatase, modulators of glucose transporter 4 (GLUT4), inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT),
GLP-1 agonists, potassium channel openers such as, for example, those which have been disclosed in
WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, inhibitors of dipeptidylpeptidase IV (DPP-IV), insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenosis, modulators of glucose uptake, of glucose transport and of glucose reabsorption, inhibitors of 11 β-HSD1 , inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), compounds which alter lipid metabolism such as antihyperlipidemic active ingredients and antilipidemic active ingredients, compounds which reduce food intake, compounds which increase thermogenesis,
PPAR and RXR modulators and active ingredients which act on the ATP-dependent potassium channel of the beta cells. In one embodiment of the invention, the compound of the formula I is administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
In one embodiment of the invention, the compound of the formula I is administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, WO 2005/042692), MD-0727 (Microbia Inc., WO 2005/021497) or with compounds as described in WO 2002/066464 (Kotobuki Pharmaceutical Co. Ltd.), WO 2005/062824 (Merck & Co.) or WO 2005/061451 and WO 2005/061452 (AstraZeneca AB).
In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483 or CS-011 (rivoglitazone).
In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 or DRF-10945.
In one embodiment of the invention, the compound of the formula I is administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, muraglitazar, tesaglitazar, naveglitazar, LY-510929, ONO-5129, E-3030 or as described in WO 00/64888, WO 00/64876, WO 03/020269, WO 2004/075891 , WO 2004/076402, WO 2004/075815, WO 2004/076447, WO 2004/076428, WO 2004/076401 , WO 2004/076426, WO 2004/076427, WO 2006/018118, WO 2006/018115, and WO 2006/018116 or in J. P. Berger et al., TRENDS in Pharmacological Sciences 28(5), 244-251 , 2005. In one embodiment of the invention, the compound of the formula I is administered in combination with a PPAR delta agonist such as, for example, GW-501516, or as described in WO 2005/097762, WO 2005/097786, WO2005/097763, WO 2006/029699.
In one embodiment of the invention, the compound of the formula I is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
In one embodiment of the invention, the compound of the formula I is administered in combination with a fibrate such as, for example, fenofibrate, clofibrate or bezafibrate.
In one embodiment of the invention, the compound of the formula I is administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757 or those described in WO 2005/085226.
In one embodiment of the invention, the compound of the formula I is administered in combination with a CETP inhibitor such as, for example, torcetrapib or JTT-705.
In one embodiment of the invention, the compound of the formula I is administered in combination with a bile acid absorption inhibitor (see, for example, US 6,245,744, US 6,221 ,897 or WO 00/61568), such as, for example, HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9.
In one embodiment of the invention, the compound of the formula I is administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine or colesevelam.
In one embodiment of the invention, the compound of the formula I is administered in combination with an LDL receptor inducer (see US 6,342,512), such as, for example, HMR1171 , HMR1586 or those as described in WO 2005/097738. In one embodiment, the compound of the formula I is administered in combination with Omacor® (Omega-3 fatty acids; highly concentrated ethyl esters of eicosapentaenoic acid and of docosahexaenoic acid).
In one embodiment of the invention, the compound of the formula I is administered in combination with an ACAT inhibitor such as, for example, avasimibe.
In one embodiment of the invention, the compound of the formula I is administered in combination with an antioxidant such as, for example, OPC-14117, probucol, tocopherol, ascorbic acid, β-carotene or selenium.
In one embodiment of the invention, the compound of the formula I is administered in combination with a vitamin such as, for example, vitamin B6 or vitamin B12.
In one embodiment of the invention, the compound of the formula I is administered in combination with a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
In one embodiment of the invention, the compound of the formula I is administered in combination with an ATP citrate lyase inhibitor such as, for example, SB-204990.
In one embodiment of the invention, the compound of the formula I is administered in combination with a squalene synthetase inhibitor such as, for example, BMS-188494 or as described in WO 2005/077907.
In one embodiment of the invention, the compound of the formula I is administered in combination with a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027). In one embodiment of the invention, the compound of the formula I is administered in combination with an HM74A receptor agonist such as, for example, nicotinic acid.
In one embodiment of the invention, the compound of the formula I is administered in combination with a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
In one embodiment of the invention, the compound of the formula I is administered in combination with insulin.
In one embodiment of the invention, the compound of the formula I is administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
In one embodiment of the invention, the compound of the formula I is administered in combination with a biguanide such as, for example, metformin.
In another embodiment of the invention, the compound of the formula I is administered in combination with a meglitinide such as, for example, repaglinide or nateglinide.
In one embodiment of the invention, the compound of the formula I is administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2- quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment of the invention, the compound of the formula I is administered in combination with an α-glucosidase inhibitor such as, for example, miglitol or acarbose.
In one embodiment of the invention, the compound of the formula I is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide. In one embodiment of the invention, the compound of the formula I is administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of glycogen phosphorylase, such as, for example, PSN- 357 or FR-258900 or those as described in WO 2003/084922, WO 2004/007455, WO 2005/073229-31 or WO 2005/067932.
In one embodiment of the invention, the compound of the formula I is administered in combination with glucagon receptor antagonists such as, for example, A-770077, NNC-25-2504 or as described in WO 2004/100875 or WO 2005/065680.
In one embodiment of the invention, the compound of the formula I is administered in combination with activators of glucokinase, such as, for example, RO-4389620, LY- 2121260 (WO 2004/063179), PSN-105, PSN-110, GKA-50 or those as are described for example by Prosidion in WO 2004/072031 , WO 2004/072066, WO 05/103021 or WO 06/016178, by Roche in WO 00/058293, WO 00/183465, WO 00/183478, WO 00/185706, WO 00/185707, WO 01/044216, GB 02385328, WO 02/008209, WO 02/014312, WO 02/46173, WO 02/48106, DE 10259786, WO 03/095438, US 04067939 or WO 04/052869, by Novo Nordisk in EP 1532980, WO 03/055482, WO 04/002481 , WO 05/049019, WO 05/066145 or WO 05/123132, by Merck/Banyu in WO 03/080585, WO 03/097824, WO 04/081001 , WO 05/063738 or WO 05/090332, by EIi Lilly in WO 04/063194, or by Astra Zeneca in WO 01/020327, WO 03/000262, WO 03/000267, WO 03/015774, WO 04/045614, WO 04/046139, WO 05/044801 , WO 05/054200, WO 05/054233, WO 05/056530, WO 05/080359, WO 05/080360 or WO 05/121110. In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of gluconeogenesis, such as, for example, FR-225654.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of fructose-1 ,6-bisphosphatase (FBPase), such as, for example, CS-917.
In one embodiment of the invention, the compound of the formula I is administered in combination with modulators of glucose transporter 4 (GLUT4), such as, for example, KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004)).
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), as are described for example in WO 2004/101528.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of dipeptidylpeptidase IV (DPP-IV), such as, for example, vildagliptin (LAF-237), sitagliptin (MK-0431), saxagliptin (BMS-477118), GSK-823093, PSN-9301 , SYR-322, SYR-619, TA-6666, TS-021 , GRC-8200, GW-825964X or as are described in WO 2003/074500, WO 2003/106456, WO 2004/50658, WO 2005/058901 , WO 2005/012312, WO 2005/012308, PCT/EP2005/007821 , PCT/EP2005/008005, PCT/EP2005/008002, PCT/EP2005/008004, PCT/EP2005/008283, DE 10 2005 012874.2 or DE 10 2005 012873.4.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 (11 β-HSD1 ), such as, for example, BVT-2733 or those as are described for example in WO 2001/90090-94, WO 2003/43999, WO 2004/112782, WO 2003/44000, WO 2003/44009, WO 2004/112779, WO 2004/113310, WO 2004/103980, WO 2004/112784, WO 2003/065983, WO 2003/104207, WO 2003/104208, WO 2004/106294, WO 2004/01 1410, WO 2004/033427, WO 2004/041264, WO 2004/037251 , WO 2004/056744, WO 2004/065351 , WO 2004/089367, WO 2004/089380, WO 2004/089470-71 , WO 2004/089896, WO 2005/016877 or WO 2005/097759.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), as are described for example in WO 2001/19830-31 , WO 2001/17516, WO 2004/506446, WO 2005/012295, PCT/EP2005/005311 , PCT/EP2005/005321 , PCT/EP2005/007151 , PCT/EP2005/01294 or DE 10 2004 060542.4.
In one embodiment of the invention, the compound of the formula I is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), such as, for example, KGA-2727, T-1095 and SGL-0010 or as are described for example in WO 2004/007517, WO 2004/52903, WO 2004/52902, WO 2005/121161 , WO 2005/085237, JP2004359630 or by A. L. Handlon in Expert Opin. Ther. Patents (2005) 15(11), 1531-1540.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of hormone-sensitive lipase (HSL) as described for example in WO 01/17981 , WO 01/66531 , WO 2004/035550, WO 2005/073199 or WO 03/051842.
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC), such as, for example, those as described in WO 1999/46262, WO 2003/72197, WO 2003/072197 or WO 2005/044814.
In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), such as, for example, those as described in WO 2004/074288. In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta), as described for example in US2005222220, WO 2004/046117, WO 2005/085230, WO 2005/111018, WO 2003/078403, WO 2004/022544, WO 2003/106410, WO 2005/058908, US2005038023, WO 2005/009997, US2005026984, WO 2005/000836, WO 2004/106343, EP1460075, WO 2004/014910, WO 2003/076442, WO 2005/087727 or WO 2004/046117.
In one embodiment of the invention, the compound of the formula I is administered in combination with an inhibitor of protein kinase C beta (PKC beta), such as, for example, ruboxistaurin.
In one embodiment of the invention, the compound of the formula I is administered in combination with an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
In one embodiment of the invention, the compound of the formula I is administered in combination with inhibitors of "l-kappaB kinase" (IKK inhibitors), as are described for example in WO 2001/000610, WO 2001/030774, WO 2004/022553 or WO 2005/097129.
In one embodiment of the invention, the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor, like those described for example in WO 2005/090336.
In a further embodiment of the invention, the compound of the formula I is administered in combination with CART modulators (see "Cocaine-amphetamine- regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558); NPY antagonists such as, for example, naphthalene-1 -sulfonic acid {4-[(4-amino- quinazolin-2-ylamino)methyl]cyclohexylmethyl}amide hydrochloride (CGP 71683A); peptide YY 3-36 (PYY3-36) or analogous compounds, such as, for example, CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34), CJC-1643 (derivative of PYY3-36 which conjugates in vivo to serum albumin) or those as are described in WO 2005/080424; cannabinoid receptor 1 antagonists such as, for example, rimonabant, SR147778 or those as are described for example in EP 0656354, WO 00/15609, WO 02/076949, WO 2005/080345, WO 2005/080328, WO 2005/080343, WO 2005/075450, WO 2005/080357, WO 2001/70700, WO 2003/026647-48, WO 2003/02776, WO 2003/040107, WO 2003/007887, WO 2003/027069, US 6,509,367, WO 2001/32663, WO 2003/086288, WO 2003/087037, WO 2004/048317, WO 2004/058145, WO 2003/084930, WO 2003/084943, WO 2004/058744, WO 2004/013120, WO 2004/029204, WO 2004/035566, WO 2004/058249, WO 2004/058255, WO 2004/058727, WO 2004/069838, US20040214837, US20040214855, US20040214856, WO 2004/096209, WO 2004/096763, WO 2004/096794, WO 2005/000809, WO 2004/099157, US20040266845, WO 2004/110453, WO 2004/108728, WO 2004/000817, WO 2005/000820, US20050009870, WO 2005/00974, WO 2004/111033-34, WO 2004/11038-39, WO 2005/016286, WO 2005/007111 , WO 2005/007628, US20050054679, WO 2005/027837, WO 2005/028456, WO 2005/063761-62, WO 2005/061509 or WO 2005/077897;
MC4 agonists (e.g. 1-amino-1 ,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2-(3a- benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4- chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)) or LB53280, LB53279, LB53278 or THIQ, MB243, RY764, CHIR-785, PT-141 or those as are described in WO 2005/060985, WO 2005/009950, WO 2004/087159, WO 2004/078717, WO 2004/078716, WO 2004/024720, US20050124652, WO 2005/051391 , WO 2004/112793, WOUS20050222014, US20050176728, US20050164914, US20050124636, US20050130988, US20040167201 , WO 2004/005324, WO 2004/037797, WO 2005/042516, WO 2005/040109, WO 2005/030797, US20040224901 , WO 2005/01921 , WO 2005/09184, WO 2005/000339, EP1460069, WO 2005/047253, WO 2005/047251 , EP1538159, WO 2004/072076,
WO 2004/072077 or WO 2006/024390; orexin receptor antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3-[1 ,5]naphthyridin-4- ylurea hydrochloride (SB-334867-A) or those as are described for example in WO 2001/96302, WO 2001/85693, WO 2004/085403 or WO 2005/075458); histamine H3 receptor agonists (e.g. 3-cyclohexyl-1-(4,4-dimethyl-1 ,4,6,7-tetrahydro- imidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208) or those as are described in WO 2000/64884, WO 2005/082893);
CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1 ,3,9-triazafluoroen-4- yl]dipropylamine (WO 00/66585));
CRF BP antagonists (e.g. urocortin); urocortin agonists; β3 agonists (such as, for example, 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-
(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]ethanol hydrochloride (WO 01/83451)); MSH (melanocyte-stimulating hormone) agonists;
MCH (melanin-concentrating hormone) receptor antagonists (such as, for example,
NBI-845, A-761 , A-665798, A-798, ATC-0175, T-226296, T-71 , GW-803430 or compounds such as are described in WO 2003/15769, WO 2005/085200,
WO 2005/019240, WO 2004/011438, WO 2004/012648, WO 2003/015769, WO 2004/072025, WO 2005/070898, WO 2005/070925, WO 2006/018280,
WO 2006/018279, WO 2004/039780, WO 2003/033476, WO 2002/006245,
WO 2002/002744, WO 2003/004027 or FR2868780);
CCK-A agonists (such as, for example, {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2- cyclohexylethyOthiazol^-ylcarbamoyll-δJ-dirnethylindol-i -yljacetic acid trifluoroacetic acid salt (WO 99/15525), SR-146131 (WO 0244150) or SSR-125180); serotonin reuptake inhibitors (e.g. dexfenfluramine); mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549);
5-HT receptor agonists, e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO
01/09111 ); 5-HT2C receptor agonists (such as, for example, APD-356, BVT-933 or those as are described in WO 2000/77010, WO 2007/7001-02, WO 2005/019180,
WO 2003/064423, WO 2002/42304 or WO 2005/082859);
5-HT6 receptor antagonists as are described for example in WO 2005/058858; bombesin receptor agonists (BRS-3 agonists); galanin receptor antagonists; growth hormone (e.g. human growth hormone or AOD-9604); growth hormone releasing compounds (tertiary butyl 6-benzyloxy-1-(2-diisopropyl- aminoethylcarbamoyl)-3,4-dihydro-1 H-isoquinoline-2-carboxylate (WO 01/85695)); growth hormone secretagogue receptor antagonists (ghrelin antagonists) such as, for example, A-778193 or those as are described in WO 2005/030734;
TRH agonists (see, for example, EP 0 462 884); uncoupling protein 2 or 3 modulators; leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C; Rozhavskaya- Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881);
DA agonists (bromocriptine or Doprexin); lipase/amylase inhibitors (like those described for example in WO 00/40569); inhibitors of diacylglycerol O-acyltransferases (DGATs) as described for example in US2004/0224997, WO 2004/094618, WO 2000/58491 , WO 2005/044250,
WO 2005/072740, JP2005206492 or WO 2005/013907; inhibitors of fatty acid synthase (FAS) such as, for example, C75 or those as described in WO 2004/005277; oxyntomodulin; oleoyl-estrone
or thyroid hormone receptor agonists such as, for example: KB-2115 or those as described in WO 2005/8279, WO 2001/72692, WO 2001/94293, WO 2003/084915, WO 2004/018421 or WO 2005/092316. In one embodiment of the invention, the further active ingredient is leptin; see, for example, "Perspectives in the therapeutic use of leptin", Salvador, Javier; Gomez- Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622.
In one embodiment of the invention, the further active ingredient is dexamphetamine or amphetamine.
In one embodiment of the invention, the further active ingredient is fenfluramine or dexfenfluramine.
In another embodiment of the invention, the further active ingredient is sibutramine.
In one embodiment of the invention, the further active ingredient is mazindole or phentermine.
In one embodiment of the invention, the compound of the formula I is administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, Carob/Caromax® (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6)). Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, lndustriepark Hoechst, 65926 Frankfurt/Main. Combination with Caromax® is possible in one preparation or by separate administration of compounds of the formula I and Caromax®. Caromax® can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
In one embodiment of the invention, the compound of the formula I is administered in combination with PDE inhibitors (phosphodiesterase), like those described for example in WO 2003/077949 or WO 2005/012485. In one embodiment of the invention, the compound of the formula I is administered in combination with NAR-1 (nicotinic acid receptor) agonists like those described for example in WO 2004/094429.
In one embodiment of the invention, the compound of the formula I is administered in combination with CB2 (cannabinoid receptor) agonists like those described for example in US2005/143448.
In one embodiment of the invention, the compound of the formula I is administered in combination with histamine 1 agonists like those described for example in WO 2005/101979.
In one embodiment of the invention, the compound of the formula I is administered in combination with bupropion as described in WO 2006/017504.
In one embodiment of the invention, the compound of the formula I is administered in combination with opioid antagonists like those described for example in WO 2005/107806 or WO 2004/094429.
In one embodiment of the invention, the compound of the formula I is administered in combination with neutral endopeptidase inhibitors like those described for example in WO 2002/02513, WO 2002/06492, WO 2002/040008, WO 2002/040022 or WO 2002/047670.
In one embodiment of the invention, the compound of the formula I is administered in combination with NPY inhibitors (neuropeptide Y) like those described for example in WO 2002/047670.
In one embodiment of the invention, the compound of the formula I is administered in combination with sodium/hydrogen exchange inhibitors like those described for example in WO 2003/092694. In one embodiment of the invention, the compound of the formula I is administered in combination with modulators of the glucocorticoid receptor like those described for example in WO 2005/090336.
In one embodiment of the invention, the compound of the formula I is administered in combination with nicotine receptor agonists like those described for example in WO 2004/094429.
In one embodiment of the invention, the compound of the formula I is administered in combination with NRIs (norepinephrine reuptake inhibitors) like those described for example in WO 2002/053140.
In one embodiment of the invention, the compound of the formula I is administered in combination with MOA (E-beta-methoxyacrylate) such as, for example, segeline or like those described for example in WO 2002/053140.
In one embodiment of the invention, the compound of the formula I is administered in combination with antithrombotic active ingredients such as, for example, clopidrogel.
It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is regarded as falling within the protection conferred by the present invention.
Some of the formulae for the development codes mentioned above are detailed hereinafter.
Figure imgf000044_0001
Figure imgf000044_0002
JTT-501
Figure imgf000044_0003
LY-674 KRP-101
Figure imgf000044_0004
LY-510929 GW-501516
Figure imgf000044_0005
Figure imgf000045_0001
NO-1886
Figure imgf000045_0002
FR-225654
Figure imgf000046_0001
Figure imgf000046_0003
Figure imgf000046_0002
Figure imgf000047_0001
Figure imgf000048_0001
The activity of the compounds of the invention of the formula I was tested in the following enzyme assay system:
EL inhibition assay:
EL is released as secretory protein in high concentration into cell culture medium (conditioned medium) by recombinant cell lines (CHO, HEK293). This is employed as an enzyme solution after concentration.
EL activity assay
The phospholipase-specific substrate 1 ,2-bis(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a- diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine (manufacturer Molecular Probes) is used to characterize the enzymatic activity of endothelial lipase and the effect of inhibitors. Hydrolysis of the A1 ester linkage of this phospholipid by the enzyme liberates a fatty acid labeled with the fluorescent dye Bodipy which can be detected after separation by thin-layer chromatography on an HPTLC plate (silica gel 60, Merck) or directly in the reaction vessel by measuring the fluorescence. The substrate solution is prepared by dissolving 100 μg of 1 ,2-bis(4,4-difluoro-5,7- dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-s/i-glycero-3-phospho-choline (manufacturer Molecular Probes) in 100 μl of DMSO and taking up in 2.4 mg of tripalmitin (Sigma) in 393 μl of chloroform which comprises 20 mg/ml of DOP-choline (1 ,2-dioleoyl-sn-glycero-3-phosphocholine). 39.3 μl of this lipid mixture are transferred into a fresh reaction vessel, and the solvent is evaporated off. The lipid mixture is dissolved in 4 ml of 200 mM TRIS-HCI, 150 mM sodium chloride, pH = 7.4, by sonicating twice. The subsequent enzymic reaction takes place at 37°C for 90 minutes. For this purpose, 20 μl of the substrate solution are incubated with 2 μl of inhibitor of appropriate concentration (dissolved in 10% DMSO, using 10% strength DMSO solution for control) and 2 μl of enzyme solution (conditioned medium). Subsequently, 4 μl of the assay mixture are loaded onto an HPTLC plate (silica gel 60, Merck), and the liberated fluorescent dye is separated for detection with a mobile phase (diethyl etherpetroleum spirit:acetic acid [78:22:1]). After evaporation of the mobile phase, the plate is read in a fluorescence scanner. An increased liberation of the fluorescent dye in the uninhibited reaction is observed as a measure of the enzyme activity.
The enzymatic activity is reduced as a function of the inhibitor concentration used, and the inhibitor concentration at which a half-maximum enzymatic activity is observed is called IC50-
In these assays, the compounds of the examples exhibited the following IC50 values:
Figure imgf000049_0001
Other test models Suitability of the compounds of the invention as active pharmaceutical ingredient can be tested by means of various test models. Descriptions are given of such test models by way of example below. Solubility in aqueous systems
Adequate solubility of a substance in aqueous solvent systems is an important prerequisite for a (reproducible) pharmacological effect. Solubilities in aqueous systems can be determined by various methods. Suitable examples of solution precipitation methods ("kinetic solubility") and methods which investigate the dissolution of a solid sample until an equilibrium is set up ("thermodynamic solubility"), a) Kinetic solubility
A DMSO solution of the test compound (2.5 mM; 0.5 μl_) is pipetted into 200 μL of an aqueous test solution (e.g. phosphate-buffered saline, 1Ox, 1 M, Sigma, adjusted to 10 mM, pH 7.4) in a 96-well microtiter plate, and the turbidity is measured at the resulting theoretical concentration for the test compound of 6.25 μM using a nephelometer (e.g. Nephelostar Galaxy, BMG Labtech). The concentration of the test compound in the aqueous test solution is then raised to a theoretical 12.5 μM by adding further DMSO solution (2.5 mM; 0.5 μL), and the turbidity measurement is repeated. Further additions of DMSO solutions (1 μL, 2.5 mM; 0.5 μL, 10 mM; then 9x 1 μL, 10 mM resulting in theoretical concentrations of 25 μM, 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM, 350 μM, 400 μM, 450 μM and 500 μM) with turbidity measurement in between complete the measurement process. Evaluation: The turbidity values from the nephelometer are plotted against the theoretical concentration of the test compound in the aqueous test solution. As soon as a significant turbidity is detected (e.g. 5 times above the control value of the aqueous test solution) at a theoretical concentration, the level of concentration below this is stated to be the solubility limit of the test compound in the test solution. Thus, the maximum possible measurement range emerges as values <6.25 μM, 6.25 - 500 μM and >500 μM.
Preferred compounds of the invention show a kinetic solubility in phosphate buffer (pH 7.4) of at least 12.5 μM; more preferably of at least 50 μM and even more preferably of at least 250 μM.
b) Thermodynamic solubility
The integrated UV absorption from HPLC UV measurement of serial dilutions of the test compound in DMSO (500 μM, 100 μM, 50 μM, 10 μM and 1 μM) shows a linear correlation with the concentration in a calibration line. The test compound (500 μg) is shaken together with the aqueous test solution (250 μl_) in a closed vessel (capacity: 1.5 ml_) for 16 hours (Eppendorf thermoshaker, 1400 rpm, 250C1 covering to protect from light). The sample is then centrifuged at maximum rotational speed, and the supernatant is finally filtered. A sample of the filtered supernatant is analyzed directly by HPLC UV measurement (see above). A further sample is analyzed after dilution (1 part by volume of supernatant, 39 parts by volume of test solution). Evaluation: The concentration of the test compound in the undiluted supernatant is calculated from the resulting integrated UV absorptions of the supernatant samples on the basis of the constructed calibration lines and stated as solubility of the test compound in the respective aqueous test solution.
Examples of aqueous test solutions are deionized water or aqueous phosphate buffer with various pH values (e.g. pH 1.2; pH 4.0; pH 6.8; pH 7.4; pH 9.0) which can be prepared from the commercial solution (phosphate buffered saline, 10x, Sigma) by dilution and adjustment with phosphoric acid or sodium hydroxide solution by standard methods.
Preferred compounds of the invention show a solubility in phosphate buffer (pH 7.4) of at least 12.5 μM; more preferably of at least 50 μM and even more preferably of at least 250 μM.
Metabolic stability
The metabolic stability is determined by incubating the test compound (5 μM) with microsomal liver fractions (1 mg/mL protein with 0.1 % w/v BSA; 1 mM NADPH, 0.5% DMSO) at 37°C. Analysis at an incubation time of 0 and 20 minutes takes place by means of LCMS/MS. Further descriptions of the test system and references for the experimental procedure are to be found in Plant, N.; Drug Discovery Today 2004, 9(7), 328-336 and Lau, Y.Y. et al.; Pharmaceutical Res. 2002, 19(11), 1606-1610. Process for preparation
The inventive compounds of the formula I are prepared by methods known per se, for example by acylating substituted or unsubstituted imidazopyridin-2-one derivatives Il with carbamoyl chlorides III (method A) or in two stages by reacting imidazopyridin-2- one derivatives Il with phosgene or equivalents, such as trichloromethyl chlorocarbonate, di(trichloromethyl) carbonate or 4-nitrophenyl chloroformate, and further reacting the resulting imidazopyridin-2-one carboxylic acid derivatives with amines IV (method B). It is likewise also possible to react the imidazopyridin-2-one derivatives Il with the corresponding isocyanates V RI-N=C=O (method C).
The R6 radicals may also be introduced subsequently by alkylating the compounds I (where R6 = hydrogen) by literature methods.
R6 radicals of the -(C=O)-NRI 'R2 type can be introduced by the abovementioned methods A, B or C. This can be done by using components IV and phosgene, or III or V in a more than 2-fold excess relative to the starting compounds II. The R6 radicals may also be introduced subsequently by the abovementioned methods A, B or C, especially when R1 and R1 ' are different.
R6 radicals of the -(C=O)-O-RI " type can be introduced by literature methods, either by reaction of unsubstituted imidazopyridin-2-ones with the corresponding chloroformates in order to arrive at the compounds of the formula II, which are reacted further as described above for A, B or C, or by subsequently reacting of compounds of the formula I where R6 = H with the corresponding chloroformates.
The compounds of the formula I obtained by above-described processes can be separated by known separation processes, for example chromatographic processes, in order to isolate, for example, monosubstituted from disubstituted imidazopyridin-2- ones.
Figure imgf000053_0001
IV '
Figure imgf000053_0002
I
Figure imgf000053_0003
Il V I
Since acids are generally released in these reactions, it is advisable to add bases such as pyridine, triethylamine, sodium hydroxide solution or alkali metal carbonates for acceleration. The reactions may be performed within wide temperature ranges. In general, it has been found to be advantageous to work at from 0°C up to the boiling point of the solvent used. The solvents used include, for example, methylene chloride, THF, DMF, toluene, ethyl acetate, n-heptane, dioxane, diethyl ether or pyridine. When anhydrous conditions are employed, strong bases such as lithium hydride, sodium hydride or potassium tert-butoxide in aprotic solvents such as THF or DMF have also been found to be useful. The imidazopyridin-2-one derivatives used are starting compounds Il are commercially available or can be prepared by literature processes (for example, G. P. Zecchini, I. Torrini and M. P. Paradisi, J. Het. Chem. (1985) 22, 313-318; G. P. Zecchini, I. Torrini and M. P. Paradisi, J. Het. Chem. (1985) 22, 1061-1064).
The examples adduced below serve to illustrate the invention but without restricting it.
The identity of the compounds was checked by mass spectrometry.
Examples
Example 1 :
N-Hexyl-1-methyl-2-oxo-1 ,2-dihydroimidazo[4,5-b]pyridine-3-carboxamide 1-Methyl-1 ,3-dihydroimidazo[4,5-b]pyridin-2-one (75 mg, 0.5 mmol) and
1-isocyanatohexane (64 mg, 0.5 mmol) were stirred at 800C in 3.5 ml of dioxane for 4 h. The reaction mixture was concentrated and purified by means of preparative HPLC (PR18, acetonitrile/water 0.1 % TFA). Yield: 40 mg (29%), M+H+: 277.16.
Example 2:
N-(2-Methylbenzyl)-1-methyl-2-oxo-1 ,2-dihydroimidazo[4,5-b]pyridine-3-carboxamide Analogously to Example 1 , 75 mg (0.5 mmol) of 1-methyl-1 ,3-dihydroimidazo[4,5- b]pyridin-2-one were reacted with 74 mg (0.5 mmol) of 1-isocyanatomethyl-2- methylbenzene in dioxane at 800C. Yield: 11 mg (7%), M+H+: 297.05.
Example 3:
N-Hexyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxamide Analogously to Example 1 , 1 ,3-dihydroimidazo[4,5-b]pyridin-2-one (100 mg, 0.74 mmol) and 1-isocyanatohexane (113 mg, 0.89 mmol) were reacted in dioxane. Yield: 75 mg (39%), M+H+: 263.15. Example 4:
N-Hexyl-3-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxamide In 2.5 ml of DMF, N-hexyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1-carboxamide (65 mg, 0.248 mmol), iodomethane (70 mg, 0.5 mmol) and cesium carbonate (80 mg, 0.25 mmol) were stirred at RT for 5 h. After concentration, the mixture was admixed with water and ethyl acetate, and the organic phase was removed, concentrated and purified by means of preparative HPLC (PR18, acetonitrile/water 0.1 % TFA). Yield: 16 mg (23%), M+H+: 277.17.
Example 5:
N-Hexyl-7-methyl-2-oxo-1 ,2-dihydroimidazo[4,5-b]pyridine-3-carboxamide Analogously to Example 1 , tert-butyl 7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine- 1-carboxylate (300 mg, 1.2 mmol), 1-isocyanatohexane (183.8 mg, 1.44 mmol) and 4- dimethylaminopyridine (14.7 mg, 0.12 mmol) were reacted in toluene. Yield: 8 mg (2%), M+H+: 277.16.
Example 6:
N-Hexyl-7-methyl-2-oxo-1 ,2-dihydroimidazo[4,5-b]pyridine-3-carboxamide Analogously to Example 1 , 2 g (14.8 mmol) of 1 ,3-dihydroimidazo[4,5-c]pyridin-2-one and 1-isocyanatohexane (2.26 g, 17.76 mmol) were reacted in toluene. Yield: 43 mg (1 %), M+H+: 263.19.
Example 7: tert-Butyl 3-hexylcarbamoyl-7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine-1- carboxylate Analogously to Example 1 , tert-butyl 7-methyl-2-oxo-2,3-dihydroimidazo[4,5-b]pyridine- 1-carboxylate (200 mg, 0.8 mmol) and 1-isocyanatohexane (113 mg, 0.88 mmol) were reacted in dioxane. Yield: 5 mg (2%), M+H+: 377.20.
Example 8:
N,N'-Bishexyl-2-oxoimidazo[4,5-c]pyridine-1 ,3-dicarboxamide
As a further compound, N,N'-bishexyl-2-oxoimidazo[4,5-c]pyridine-1 ,3-dicarboxamide was isolated from the mixture in Example 6. Yield: 16 mg (1 %), M+H+: 390.28.
Example 9:
1-Methyl-2-oxo-1 ,2-dihydro-imidazo[4,5-b]pyridine-3-carboxylic acid-(R)-indan-1- ylamide
As a further example 1-Methyl-2-oxo-1 ,2-dihydro-imidazo[4,5-b]pyridine-3-carboxylic acid-(R)-indan-1-ylamide was prepared analogously: M+H+: 309.21.

Claims

Claims
1. A compound of the formula I
where:
Figure imgf000057_0001
X is the same or different and is =C(-R)- or =N-, where at least one X and at most two X are =N-;
W is -(C=O)-, -(S=O)-, -(SO2)-;
R is the same or different and is hydrogen, halogen, (CrC6)-alkyl, (Ci-C3)- haloalkyl, (Ci-C3)-alkyloxy-(Ci-C3)-alkylene, aryl, heterocycle, hydroxyl, (CrC6)-alkyloxy, (CrC3)-haloalkyloxy, aryloxy, cyano, nitro, -S(O)p-(Cr C6)-alkyl, where p= 0, 1 or 2, aminosulfonyl, pentafluorosulfanyl, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, (Ci-C6)-alkylcarbonyl, COOR3, CO-NR4R5 , O-CO-NR4R5, O-CO-(CrC6)-alkylene-CO-O-(C1-
C6)-alkyl, O-CO-(Ci-C6)-alkylene-CO-OH, O-CO-(CrC6)-alkylene-CO- NR4R5;
R1 , R1 ' are the same or different and are each (C5-Ci6)-alkyl, (C5-C12)-cycloalkyl, (d-CO-alkylenearyl, (Ci-C4)-alkyleneheteroaryl, (Ci-C4)-alkylene-(C5-
Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (d-CβJ-alkyl, (CrCβ)- alkyloxy, hydroxyl, (Ci-C6)-alkylmercapto, amino, (CrC6)-alkylamino, di- (C2-Ci2)-alkylamino, mono-(Ci-C6)-alkylaminocarbonyl, di-(C2-C8)- alkylaminocarbonyl, (CrC6)-alkyloxycarbonyl, (CrC^-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, pentafluorosulfanyl, (C-i- C6)-alkylsulfonyl, aminosulfonyl;
R1 " is (Ci-Ci6)-alkyl, (C5-Ci2)-cycloalkyl, (Ci-C4)-alkylenearyl, (CrC4)- alkyleneheteroaryl, (Ci-C4)-alkylene-(C5-Ci2)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, (C1-C6)- alkylmercapto, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono- (Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (Ci-C6)- alkyloxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, (Ci-C6)-alkylsulfonyl, aminosulfonyl;
R2 is hydrogen;
R3 is the same or different and is hydrogen, (Ci-C6)-alkyl, benzyl;
R4, R5 are the same or different and are each hydrogen, (C-i-C6)-alkyl, aryl, (C3-
Ci2)-cycloalkyl, (CrC4)-alkylenearyl, (CrC3)-alkylene-(C3-Ci2)-cycloalkyl;
R6 is hydrogen, (Ci-CiO)-alkyl, (CrC4)-alkylenearyl, (Ci-C4)-alkylene- heterocycle, (CrC4)-alkylene-(C3-Ci2)-cycloalkyl, bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (CrC6)-alkyloxy, hydroxyl, (Ci-C6)- alkylmercapto, amino, (CrCe)-alkylamino, di-(C2-C12)-alkylamino, mono- (CrC6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (Ci-C6)- alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, trifluoromethyl, trifluoromethyloxy, cyano, (CrC6)-alkylsulfonyl, aminosulfonyl; or
-(C=O)-NRI 'R2; or
-(C=O)-O-RI "; with the proviso that, when R1 is (C5-Ci6)-alkyl, R6 is not (Ci-C4)-alkylenearyl, (C1-C4)- alkylene-heterocycle, (Ci-C4)-alkylene-(C3-Ci2)-cycloalkyl or bicycle;
the tautomeric forms of the compound and its physiologically compatible salts.
2. A compound of the formula I as claimed in claim 1 , in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-.
3. A compound of the formula I as claimed in claim 1 or 2, in which
W is -(C=O)-.
4. A compound of the formula I as claimed in any of claims 1 to 3, in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, (Ci-C6)-alkyl, hydroxyl, phenoxy, trifluoromethyl, COOR3, pentafluorosulfanyl, amino, (C1-C6)- alkylamino, di-(C2-C8)-alkylamino, (CrC6)-alkylsulfonyl, aminosulfonyl, phenyl, (C5-C7)-heterocycle, (CrC6)-alkylcarbonyl, CO-NR4R5, O-CO- NR4R5, O-CO-(C1-C6)-alkylene-CO-O-(Ci-Cβ)-alkyl, 0-CO-(C1-C6)- alkylene-CO-NR4R5 or unsubstituted or mono- or poly-F-substituted (C1- C3)-alkyloxy; R1 , R1 ' are the same or different and are each (C6-Ci2)-alkyl, (Ci-C3)- alkylenearyl, (CrC3)-alkylene-heterocycle, (Ci-C3)-alkylene-(C5-Ci2)- cycloalkyl, (C8-C14)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-CβJ-alkyl, (CrC3)-alkyloxy, hydroxyl, amino, (CrCβJ-alkylamino, (Ci-Cβ)- alkyloxycarbonyl,
Figure imgf000060_0001
cyano, trifluoromethyl, trifluoromethyloxy;
R1 " is (Ci-Ci2)-alkyl, (CrC3)-alkylenearyl, (CrC3)-alkylene-heterocycle, (Ci-C3)-alkylene-(C5-Ci2)-cycloalkyl, (C8-Ci4)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, amino, (Ci-C6)-alkylamino, (CrC^-alkyloxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R2 is hydrogen;
R3 is hydrogen, (CrC6)-alkyl, benzyl;
R4, R5 are the same or different and are each hydrogen, (Ci-C6)-alkyl, (C3-Ci2)- cycloalkyl, phenyl, (Ci-C4)-alkylenephenyl, (Ci-C4)-alkylene-(C4-Ci2)- cycloalkyl;
R6 is hydrogen, (Ci-Cio)-alkyl, (CrC4)-alkylenephenyl, (Ci-C4)-alkylene- heterocycle, (d-C4)-alkylene-(C3-C12)-cycloalkyl, where penyl, heterocycle, cycloalkyl may be mono- or polysubstituted preferably by halogen, (CrC6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, (Ci-C6)- alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (Ci-C6)-alkylsulfonyl; or
-(C=O)-NRI R2 or
-(C=O)-O-RI "; the tautomeric forms of the compound and its physiologically compatible salts.
5. A compound of the formula I as claimed in any of claims 1 to 4, in which
X in positions 5 and 6 are identical or different and are each =C(-R)-, and in position 7 or 4 is =N-.
6. A compound of the formula I as claimed in any of claims 1 to 5, in which
X in positions 4, 5 and 6 are identical or different and are each =C(-R)-, and in position 7 is =N-.
7. A compound of the formula I as claimed in any of claims 1 to 6, in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, (C-i-CεJ-alkyl, trifluoromethyl, hydroxyl, amino, (CrC6)-alkylcarbonyl, COOR3, (CrC6)- alkylsulfonyl, pentafluorosulfanyl, or unsubstituted or mono- or poly-F- substituted (Ci-C3)-alkyloxy;
R1 , R1 ' are the same or different and are each (C6-Cio)-alkyl, -CH2-phenyl, (C-i- C2)-alkylene-heteroaryl or bicycle of the formula Ic Ic
Figure imgf000062_0001
where q = 1 or 2, where phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (CrCδJ-alkyl, (Ci-CβJ-alkyloxy, hydroxyl, amino, (CrC6)-alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R1 " is (CrC-ιo)-alkyl, -CH2-phenyl, (Ci-C2)-alkylene-heteroaryl or bicycle of the formula Ic
Ic
Figure imgf000062_0002
where q = 1 or 2, where phenyl, heteroaryl or bicycle of the formula Ic may be mono- to disubstituted preferably by halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, amino, (Ci-C6)-alkoxycarbonyl, (CrC^-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy;
R2 is hydrogen;
R3 is hydrogen, (CrC6)-alkyl;
R6 is hydrogen, (d-CβJ-alkyl, (Ci-C4)-alkylenephenyl, (Ci-C4)-alkylene- heteroaryl, where phenyl or heteroaryl may be mono- or polysubstituted by halogen, (CrC6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, (Ci-C6)- alkoxycarbonyl, (Ci-C6)-alkylcarbonyl, trifluoromethyl; or -(C=O)-NRI 'R2 or -(C=O)-O-RI "; the tautomeric forms of the compound and its physiologically compatible salts.
8. A compound of the formula I as claimed in any of claims 1 to 7, in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, halogen, hydroxyl, (CrCβ)- alkyloxy, trifluoromethyl, (Ci-C6)-alkylcarbonyl or (Ci-Cβ)-alkyl;
R1 , R1 ' are the same or different and are each (C6-Cio)-alkyl, -Chb-phenyl or bicycle of the formula Ic
Ic
Figure imgf000063_0001
where q = 1 or 2, where phenyl or bicycle may be mono- to disubstituted by halogen, (d-C6)-alkyl, (C-i-C3)-alkyloxy, (CrCθJ-alkylcarbonyl, trifluoromethyl;
R1 " is (Ci-Cio)-alkyl, -CH2-phenyl or bicycle of the formula Ic
Ic
Figure imgf000063_0002
where q = 1 or 2, where phenyl or bicycle may be mono- to disubstituted by halogen, (Ci-C6)-alkyl, (CrC3)-alkyloxy, (Ci-C6)-alkylcarbonyl, trifluoromethyl;
R2 is hydrogen; R6 is hydrogen, (CrC4)-alkyl, CH2-phenyl, where phenyl may be mono- or polysubstituted by halogen, (C-i-C6)-alkyl, (Ci-C3)-alkyloxy, hydroxyl, (Cr
CβJ-alkylcarbonyl, trifluoromethyl; or -(C=O)-NRI 'R2 or
-(C=O)-O-RI "; the tautomeric forms of the compound and its physiologically compatible salts.
9. A compound of the formula I as claimed in any of claims 1 to 8, in which
X is the same or different and is =C(-R)- or =N-, where one X is =N-;
W is -(C=O)-;
R is the same or different and is hydrogen, methyl;
R1 , RT are the same or different and are each (C6-Ci0)-alkyl, -CH2-phenyl or bicycle of the formula Id
Figure imgf000064_0001
where q = 1 , where phenyl or bicycle may be substituted by methyl;
R2 is hydrogen;
R6 is hydrogen, methyl, or
-(C=O)-NRI 'R2; the tautomeric forms of the compound and its physiologically compatible salts.
10. A medicament comprising one or more compounds of the formula I as claimed in any of claims 1 to 9.
11. The medicament as claimed in claim 9, which comprises, as a further active ingredient, one or more antidiabetics, active hypoglycemic ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin antagonists, H3 agonists, TNF agonists, CRF antagonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.
12. The use of the compounds of the formula I as claimed in any of claims 1 to 9 or of the compounds of the formula I1 in which X is the same or different and is =C(-R)- or =N-, where at least one X and at most two X are =N-;
W is -(C=O)-, -(S=O)-, -(SO2)-;
R is the same or different and is hydrogen, halogen, (CrC6)-alkyl, (C1-C3)- haloalkyl, (C-ι-C3)-alkyloxy-(Ci-C3)-alkylene, aryl, heterocycle, hydroxyl, (CrC6)-alkyloxy, (Ci-C3)-haloalkyloxy, aryloxy, cyano, nitro, -S(O)P-(C1- C6)-alkyl, where p = O, 1 or 2, aminosulfonyl, pentafluorosulfanyl, amino, (CrCβJ-alkylamino, di-(C2-Ci2)-alkylamino,
Figure imgf000066_0001
COOR3, CO-NR4R5 , O-CO-NR4R5, O-CO-(Ci-C6)-alkylene-CO-O-(Cr C6)-alkyl, O-CO-(CrC6)-alkylene-CO-OH, O-CO-(Ci-Cβ)-alkylene-CO- NR4R5;
R1 , R1 ' are the same or different and are each (C5-C16)-alkyl, (C5-Ci2)-cycloalkyl, (CrC^-alkylenearyl, (C-i-C-O-alkyleneheteroaryl, (CrC4)-alkylene-(C5- C12)-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (C-ι-C6)-alkyl, (C1-C6)- alkyloxy, hydroxyl, (C-i-C^-alkylmercapto, amino, (CrC6)-alkylamino, di- (C2-C12)-alkylamino, mono^CrCβJ-alkylaminocarbonyl, di-(C2-C8)- alkylaminocarbonyl, (d-C6)-alkyloxycarbonyl, (CrC6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, pentafluorosulfanyl, (C1- C6)-alkylsulfonyl, aminosulfonyl;
R1 " is (Ci-Ciβ)-alkyl, (C5-C12)-cycloalkyl, (CrC^-alkylenearyl, (C1-C4)- alkyleneheteroaryl, (CrC^y-alkylene-tCs-C^-cycloalkyl, bicycle, where aryl, heteroaryl, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (CrCβJ-alkyl, (C-t-C6)-alkyloxy, hydroxyl, (CrCβ)- alkylmercapto, amino, (CrC6)-alkylamino, di-(C2-C12)-alkylamino, mono- (Ci-CeJ-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (C1-C6)- alkyloxycarbonyl, (CrC6)-alkylcarbonyl, cyano, nitro, trifluoromethyl, trifluoromethyloxy, (Ci-C6)-alkylsulfonyl, aminosulfonyl;
R2 is hydrogen;
R3 are the same or different and are each hydrogen, (d-CβJ-alkyl, benzyl;
R4, R5 are the same or different and are each hydrogen, (Ci-C6)-alkyl, aryl, (C3-
Ci2)-cycloalkyl, (Ci-C4)-alkylenearyl, (CrC3)-alkylene-(C3-Ci2)-cycloalkyl;
R6 is hydrogen, (Ci-C10)-alkyi, (Ci-C4)-alkylenearyl, (Ci-C4)-alkylene- heterocycle, (CrC4)-alkylene-(C3-Ci2)-cycloalkyl, (C8-Ci4)-bicycle, where aryl, heterocycle, cycloalkyl or bicycle may be mono- or polysubstituted preferably by halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy, hydroxyl, (CrC6)- alkylmercapto, amino, (Ci-C6)-alkylamino, di-(C2-Ci2)-alkylamino, mono-
(Ci-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (Ci-Cε)- alkoxycarbonyl, (CrC6)-alkylcarbonyl, trifluoromethyl, trifluoromethyloxy, cyano, (Ci-C6)-alkylsulfonyl, aminosulfonyl; or -(C=O)-NR1 'R2; or
-(C=O)-NH2; or
-(C=O)-O-RI ";
the tautomeric forms of the compound and its physiologically compatible salts for producing a medicament for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders.
13. The use of the compound of the formula I as claimed in any of claims 1 to 9 or 12 for producing a medicament for the treatment and/or prevention of dyslipidemias and their consequences.
14. The use of the compound of the formula I as claimed in any of claims 1 to 9 or 12 for producing a medicament for the treatment and/or prevention of disorders associated with metabolic syndrome, and also in the case of disorders in which insulin resistance plays a roll, or for the treatment and/or prevention of diabetes mellitus and the associated sequelae.
15. The use of the compound of the formula I as claimed in any of claims 1 to 9 or 12 for producing a medicament for the treatment and/or prevention of disorders associated with a reduced HDL level.
16. The use of the compound of the formula I as claimed in any of claims 1 to 9 or 12 for producing a medicament for the treatment and/or prevention of atherosclerotic disorders.
17. The use of the compound of the formula I as claimed in any of claims 1 to 9 or 12 in combination with at least one further active ingredient for producing a medicament for the treatment and/or prevention of disorders in which insulin resistance plays a roll.
18. A process for producing a medicament comprising one or more of the compounds of the formula I as claimed in any of claims 1 to 9, which comprises mixing it with a pharmaceutically suitable carrier and converting this mixture to a form suitable for administration.
PCT/EP2007/002637 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase WO2007110215A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2009501922A JP2009531356A (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of vascular endothelial lipase
AU2007229708A AU2007229708A1 (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase
BRPI0709211-3A BRPI0709211A2 (en) 2006-03-28 2007-03-26 imidazopyridin-2-one derivatives as endothelial lipase inhibitors
EP07723584A EP2001878B1 (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase
AT07723584T ATE528307T1 (en) 2006-03-28 2007-03-26 IMIDAZOPYRIDINE-2-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELLIPASE
CA002647422A CA2647422A1 (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase
MX2008012126A MX2008012126A (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase.
US12/235,053 US7897616B2 (en) 2006-03-28 2008-09-22 Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
NO20084419A NO20084419L (en) 2006-03-28 2008-10-21 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006014685.9 2006-03-28
DE102006014685A DE102006014685A1 (en) 2006-03-28 2006-03-28 New bicyclic imidazolone derivatives useful as endothelial lipase inhibitors, e.g. for treating disorders of fat metabolism or glucose utilization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/235,053 Continuation US7897616B2 (en) 2006-03-28 2008-09-22 Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases

Publications (1)

Publication Number Publication Date
WO2007110215A1 true WO2007110215A1 (en) 2007-10-04

Family

ID=38179814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002637 WO2007110215A1 (en) 2006-03-28 2007-03-26 Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase

Country Status (14)

Country Link
US (1) US7897616B2 (en)
EP (1) EP2001878B1 (en)
JP (1) JP2009531356A (en)
KR (1) KR20080104341A (en)
CN (1) CN101405288A (en)
AT (1) ATE528307T1 (en)
AU (1) AU2007229708A1 (en)
BR (1) BRPI0709211A2 (en)
CA (1) CA2647422A1 (en)
DE (1) DE102006014685A1 (en)
MX (1) MX2008012126A (en)
NO (1) NO20084419L (en)
TW (1) TW200815434A (en)
WO (1) WO2007110215A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010044441A1 (en) 2008-10-17 2010-04-22 塩野義製薬株式会社 Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
WO2011074560A1 (en) 2009-12-15 2011-06-23 塩野義製薬株式会社 Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012030165A2 (en) 2010-08-31 2012-03-08 서울대학교산학협력단 Use of the fetal reprogramming of a ppar δ agonist
WO2013049096A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013048942A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048982A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048930A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013151877A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
WO2013151923A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase
WO2014011461A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Amide or urea substituted benzothiazole derivatives as inhibitors of endothelial lipase
WO2014011513A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2015105749A1 (en) 2014-01-07 2015-07-16 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
US9169240B2 (en) 2012-09-11 2015-10-27 Bristol-Myers Squibb Company Ketone linked benzothiazole inhibitors of endothelial lipase
WO2017214005A1 (en) 2016-06-06 2017-12-14 Bristol-Myers Squibb Company 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034741A1 (en) * 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
CA2779303A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144341A (en) * 1975-05-28 1979-03-13 Merck & Co., Inc. Imidazo pyridine-2-ones and pharmaceutical compositions and methods of treatment utilizing same
WO2005073199A1 (en) * 2004-02-02 2005-08-11 Sanofi-Aventis Deutschland Gmbh Indazole derivatives as inhibitors of hormone-sensitive lipases
WO2006097808A1 (en) * 2005-03-15 2006-09-21 Pfizer Japan Inc. Benzimidazolone derivatives as cb2 receptor ligands
WO2006131231A1 (en) * 2005-06-09 2006-12-14 Sanofi-Aventis Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128232A1 (en) * 2000-10-12 2002-09-12 Henderson Scott A. Heterocyclic angiogenesis inhibitors
EP1753423A4 (en) * 2004-05-28 2009-10-21 Merck & Co Inc Benzoureas having anti-diabetic activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144341A (en) * 1975-05-28 1979-03-13 Merck & Co., Inc. Imidazo pyridine-2-ones and pharmaceutical compositions and methods of treatment utilizing same
WO2005073199A1 (en) * 2004-02-02 2005-08-11 Sanofi-Aventis Deutschland Gmbh Indazole derivatives as inhibitors of hormone-sensitive lipases
WO2006097808A1 (en) * 2005-03-15 2006-09-21 Pfizer Japan Inc. Benzimidazolone derivatives as cb2 receptor ligands
WO2006131231A1 (en) * 2005-06-09 2006-12-14 Sanofi-Aventis Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
WO2010044441A1 (en) 2008-10-17 2010-04-22 塩野義製薬株式会社 Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
JPWO2010044441A1 (en) * 2008-10-17 2012-03-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
JP5605844B2 (en) * 2008-10-17 2014-10-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
WO2011074560A1 (en) 2009-12-15 2011-06-23 塩野義製薬株式会社 Oxadiazole derivative having endothelial lipase inhibitory activity
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
JP5791150B2 (en) * 2009-12-15 2015-10-07 塩野義製薬株式会社 Oxadiazole derivatives having vascular endothelial lipase inhibitory activity
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012030165A2 (en) 2010-08-31 2012-03-08 서울대학교산학협력단 Use of the fetal reprogramming of a ppar δ agonist
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048982A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9120794B2 (en) 2011-09-27 2015-09-01 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013049096A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8933235B2 (en) 2011-09-30 2015-01-13 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013048930A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013048942A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
US9394260B2 (en) 2012-04-03 2016-07-19 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
WO2013151923A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase
WO2013151877A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
US9199946B2 (en) 2012-04-03 2015-12-01 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
US8680090B2 (en) 2012-07-09 2014-03-25 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
US9139578B2 (en) 2012-07-09 2015-09-22 Bristol-Myers Squibb Company Amide or urea containing benzothiazole inhibitors of endothelial lipase
WO2014011513A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
WO2014011461A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Amide or urea substituted benzothiazole derivatives as inhibitors of endothelial lipase
US8987314B2 (en) 2012-07-19 2015-03-24 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
US9169240B2 (en) 2012-09-11 2015-10-27 Bristol-Myers Squibb Company Ketone linked benzothiazole inhibitors of endothelial lipase
WO2015105749A1 (en) 2014-01-07 2015-07-16 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
US10173991B2 (en) 2014-01-07 2019-01-08 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2017214005A1 (en) 2016-06-06 2017-12-14 Bristol-Myers Squibb Company 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors

Also Published As

Publication number Publication date
TW200815434A (en) 2008-04-01
KR20080104341A (en) 2008-12-02
EP2001878B1 (en) 2011-10-12
ATE528307T1 (en) 2011-10-15
US7897616B2 (en) 2011-03-01
NO20084419L (en) 2008-11-26
BRPI0709211A2 (en) 2011-06-28
DE102006014685A1 (en) 2007-10-04
CN101405288A (en) 2009-04-08
JP2009531356A (en) 2009-09-03
AU2007229708A1 (en) 2007-10-04
US20090076068A1 (en) 2009-03-19
CA2647422A1 (en) 2007-10-04
EP2001878A1 (en) 2008-12-17
MX2008012126A (en) 2008-10-03

Similar Documents

Publication Publication Date Title
US7897616B2 (en) Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases
US8148395B2 (en) Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8357698B2 (en) Diacyl indazole derivatives as lipase and phospholipase inhibitors
US7718669B2 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
US8735437B2 (en) Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
RU2430096C2 (en) Carbamoyl benzotriazole derivatives as lipase and phospholipase inhibitors
US9029400B2 (en) 5-oxoisoxazoles as inhibitors of lipases and phospholipases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723584

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007723584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 194247

Country of ref document: IL

Ref document number: 200780010177.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012126

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2647422

Country of ref document: CA

Ref document number: 1020087023444

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007229708

Country of ref document: AU

Ref document number: 2009501922

Country of ref document: JP

Ref document number: 5180/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007229708

Country of ref document: AU

Date of ref document: 20070326

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0709211

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080926